var title_f40_9_41104="Chylomicron metabolism";
var content_f40_9_41104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exogenous pathway of lipid metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the intestinal cell, absorbed free fatty acids combine with glycerol to form triglycerides, and, to a lesser degree, absorbed cholesterol is esterified to form cholesteryl esters. These lipids are assembled as chylomicrons; the main apolipoprotein (apo) is B-48, but apo C-II and E are acquired as the chylomicrons enter the circulation. Apo C-II is a cofactor for lipoprotein lipase which makes the chylomicrons progressively smaller in part by hydrolyzing the core triglycerides and releasing free fatty acids. The chylomicron remnants that are cleared from the circulation by hepatic chylomicron remnant receptors for which apo E is a high-affinity ligand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41104=[""].join("\n");
var outline_f40_9_41104=null;
var title_f40_9_41105="Patient information: Postpartum depression (The Basics)";
var content_f40_9_41105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/6/24675\">",
"         Patient information: Medicines for depression (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/24/21894\">",
"         Patient information: Depression treatment options for adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Postpartum depression (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/postpartum-depression-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10515609\">",
"      <span class=\"h1\">",
"       What is postpartum depression?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Postpartum depression is a kind of depression that some women get after having a baby. &ldquo;Postpartum&rdquo; is another word for the period of time shortly after a woman gives birth. Most women with postpartum depression start having symptoms within a month after giving birth. But it can be up to 12 months before a woman starts having symptoms.",
"     </p>",
"     <p>",
"      Depression can make you feel sad, down, hopeless, or cranky most of the day, almost every day. Another common sign of depression is no longer enjoying or caring about things you used to like to do.",
"     </p>",
"     <p>",
"      After having a baby, many women get a mild type of postpartum depression called postpartum blues. Within 2 or 3 days after giving birth, women with postpartum blues might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Be moody, irritable, or anxious",
"       </li>",
"       <li>",
"        Have trouble concentrating or sleeping",
"       </li>",
"       <li>",
"        Have crying spells",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In women with postpartum blues, these symptoms are not severe and usually go away within 2 weeks. But in women with postpartum depression, the symptoms are more severe and last longer.",
"     </p>",
"     <p>",
"      Women who have a history of depression are more likely to get postpartum depression than women who have never been depressed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515624\">",
"      <span class=\"h1\">",
"       What are the symptoms of postpartum depression?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be hard to tell if a woman has postpartum depression, since some of the symptoms might also be caused by the",
"      <strong>",
"      </strong>",
"      stress of taking care of a newborn. For example, it&rsquo;s normal for new mothers to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sleep too much or too little",
"       </li>",
"       <li>",
"        Feel tired or lack energy",
"       </li>",
"       <li>",
"        Have changes in their appetite, weight, and desire to have sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      But women with postpartum depression might not be able to sleep even when their babies sleep. Or they might have so little energy that they cannot get out of bed for hours.",
"     </p>",
"     <p>",
"      They might also feel:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Anxious, irritable, and angry",
"       </li>",
"       <li>",
"        Guilty or overwhelmed",
"       </li>",
"       <li>",
"        Unable to care for their baby",
"       </li>",
"       <li>",
"        Like a failure as a mother",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515640\">",
"      <span class=\"h1\">",
"       If you want to hurt or kill yourself, see someone right away!",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you ever feel like you might want to hurt yourself or your baby, do one of these things:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Call your doctor or nurse and tell them it is urgent",
"       </li>",
"       <li>",
"        Call 9-1-1 or an ambulance",
"       </li>",
"       <li>",
"        Go to the emergency room at your local hospital",
"       </li>",
"       <li>",
"        Call the National Suicide Prevention Lifeline: 1-800-273-8255;",
"        <a class=\"external\" href=\"file://www.suicidepreventionlifeline.org/\">",
"         www.suicidepreventionlifeline.org",
"        </a>",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515655\">",
"      <span class=\"h1\">",
"       How is postpartum depression treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments for depression can also be used to treat postpartum depression. The two main treatments for depression are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Taking medicines to relieve depression",
"       </li>",
"       <li>",
"        Talking with a therapist (such as a psychiatrist, psychologist, nurse, or social worker)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Women who are breastfeeding might need to avoid certain medicines. When a nursing mother takes medicine, small amounts of the medicine can be found in her breast milk. This might be unhealthy for the baby. But not treating depression can also be harmful for both the mother and her baby. Your doctor can help you decide if you need medicine and the best one to take.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515670\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who have postpartum depression once are likely to get it again. If you had postpartum depression before and took a medicine that helped you feel better, your doctor might recommend that you take that medicine again after you give birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10515685\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/6/24675?source=see_link\">",
"       Patient information: Medicines for depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=see_link\">",
"       Patient information: Depression treatment options for adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/9/41105?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16996 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41105=[""].join("\n");
var outline_f40_9_41105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515609\">",
"      What is postpartum depression?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515624\">",
"      What are the symptoms of postpartum depression?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515640\">",
"      If you want to hurt or kill yourself, see someone right away!",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515655\">",
"      How is postpartum depression treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515670\">",
"      What if I want to get pregnant again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10515685\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/6/24675?source=related_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_9_41106="Laryngeal mask airway position";
var content_f40_9_41106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Laryngeal mask airway position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The correct placement of the LMA is shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41106=[""].join("\n");
var outline_f40_9_41106=null;
var title_f40_9_41107="Ruptured thoracic aortic aneurysm on chest film";
var content_f40_9_41107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ruptured thoracic aortic aneurysm on chest film",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain radiograph of the chest demonstrates a large aneurysm of the descending aorta (white arrow). The large left pleural effusion (black arrows) is a result of rupture of the aneurysm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41107=[""].join("\n");
var outline_f40_9_41107=null;
var title_f40_9_41108="Lichen sclerosis with ecchymosis";
var content_f40_9_41108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Areas of ecchymosis from minor trauma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41108=[""].join("\n");
var outline_f40_9_41108=null;
var title_f40_9_41109="Acetabular posterior wall and column fractures";
var content_f40_9_41109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Acetabular posterior wall and column fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The anteroposterior pelvis radiograph shows the disruption of the ilioischial (black arrow) but not the iliopectineal lines (black arrowheads), and the ischial ramus fracture is present (white arrowhead). The posterior wall fragment can be appreciated overlying the roof of the acetabulum (white arrow).",
"    <br>",
"     (B) The obturator oblique view shows the displaced posterior wall fragment (white arrow), the ischial ramus fracture (white arrowhead), and the intact iliopectineal line (black arrowhead).",
"     <br>",
"      (C) The iliac oblique demonstrates the disruption of the greater sciatic notch and the posterior wall fragment superimposed on the roof of the acetabulum (black arrow).",
"      <br>",
"       (D) This computed tomography section shows the posterior wall fracture (arrow) with a column fracture line typical of a posterior column fracture (black arrowheads).",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41109=[""].join("\n");
var outline_f40_9_41109=null;
var title_f40_9_41110="Vascular supply optic nerve";
var content_f40_9_41110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Arterial supply to optic nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 619px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Baig, MN, Lubow, M, Immesoete, P, et al. Vision loss after spine surgery: review of the literature and recommendations. Neurosurg Focus 2007; 23:15.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41110=[""].join("\n");
var outline_f40_9_41110=null;
var title_f40_9_41111="Withdrawal of immunosuppression after renal transplant failure";
var content_f40_9_41111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Withdrawal of immunosuppression after renal transplant failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41111/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41111/contributors\">",
"     Brent W Miller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41111/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41111/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41111/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41111/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/9/41111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last few decades, the long-term survival of renal allografts has significantly increased. Despite this success, a substantial number of renal allograft recipients eventually require the permanent reinstitution of renal replacement therapy because of allograft failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, approximately 13 percent of patients who received a renal allograft in 2006 had undergone a previous transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, among over 100,000 patients beginning dialysis in 2002, four percent had a failed renal allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival of such patients on dialysis appears to be relatively poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. In a study of 4743 renal transplant recipients in Canada, for example, the risk of death was significantly higher with allograft failure versus those with continued allograft function (adjusted hazard ratio of 3.4, 95% CI 2.75-4.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reinstitution of dialysis after renal transplant failure presents the clinician with the dilemma of whether to withdraw immunosuppressive medications, and if withdrawal is initiated, the optimal method of tapering such therapy. The issues that must be addressed with the withdrawal of immunosuppression after renal transplant failure are reviewed herein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REASONS FOR WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most compelling reasons to withdraw immunosuppressive medications in dialysis patients with a failed renal transplant are the increased risk of infection, malignancy, and complications associated with long-term corticosteroid immunosuppression use. Infection is the second leading cause of death in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/8\">",
"     8",
"    </a>",
"    ]. Another problem is that the dosing of some immunosuppressive agents is difficult in patients with renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased risk of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of serious infections is observed in both transplant recipients (because of the direct effects of immunosuppressive medications) and dialysis patients (because of immune system derangements from uremia and access-related problems). These factors contribute to the unacceptably high incidence of infection in dialysis patients who continue to receive immunosuppressive medications after a renal allograft has failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 197 patients returning to dialysis, the risk of infection was significantly increased in patients remaining on low dose immunosuppression compared to those in whom immunosuppression was withdrawn (1.7 versus 0.5",
"      <span class=\"nowrap\">",
"       infections/patient-year,",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/10\">",
"       10",
"      </a>",
"      ]. Mortality and cardiovascular disease (odds ratios of 3.4 and 4.9) were also increased in the group on immunosuppression. Overall, the nephrectomy rate was 55 percent.",
"     </li>",
"     <li>",
"      Similar results were noted in a second retrospective review of a long- versus short-taper protocol: more infections occurred in the long-taper group (0.87 versus 0.72",
"      <span class=\"nowrap\">",
"       infections/patient-year)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/11\">",
"       11",
"      </a>",
"      ]. Most infections were dialysis-related.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4788554\">",
"    <span class=\"h2\">",
"     Increased risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of malignancy may occur in patients exposed to immunosuppression and decreased by immunosuppression withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/12\">",
"     12",
"    </a>",
"    ]. This was suggested by a retrospective cohort study consisting of over 8000 first transplant recipients in the Australia and New Zealand Dialysis and Transplantation Registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the incidence of cancers after allograft failure in kidney transplant recipients was highly variable, the incidence of Kaposi&rsquo;s sarcoma and non-Hodgkin&rsquo;s lymphoma decreased markedly on reinstitution of dialysis as did the incidence of lip cancer and melanoma. The decreased risk was generally observed for cancers associated with viral associations such as Kaposi&rsquo;s sarcoma, which is associated with human herpes type 8, and non-Hodgkin&rsquo;s lymphoma which is associated with Epstein Barr virus. The decreased risk of lip cancer may have been due to the association of human papillomavirus and skin cancers. Although melanoma has no known infectious etiology, a causal relationship between immunosuppression and its development in recipients of kidney transplants has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complications of corticosteroid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on long-term corticosteroid therapy are at risk infectious as well as non-infectious complications, including osteoporosis, muscle wasting, cataracts, and hyperglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) These are important issues given the long current waiting period in the United States for another renal allograft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Altered drug dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the standard immunosuppressive agents have special considerations in patients with severe renal impairment. As an example, although calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) are not metabolized or excreted by the kidney, their neurotoxicity may compound the neurologic effects of uremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continued administration of immunosuppressive medications to patients with renal allograft failure would, at first glance, appear to be unnecessary, since such agents increase the risk of infection without providing obvious benefits. However, the withdrawal of immunosuppression may be associated with significant complications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Precipitation of rejection, possibly requiring transplant nephrectomy",
"     </li>",
"     <li>",
"      Secondary adrenal insufficiency",
"     </li>",
"     <li>",
"      Loss of residual renal function",
"     </li>",
"     <li>",
"      Potentially adverse immunologic effects among those pursuing another transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rejection and transplant nephrectomy after withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major effect of withdrawing immunosuppressive therapy is the possible precipitation of rejection, an event that may require allograft removal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58383 \" href=\"mobipreview.htm?17/19/17712\">",
"     image 1",
"    </a>",
"    ). Although transplant nephrectomy is a relatively safe, straightforward procedure, the addition of another major event at the same time of reinitiation of dialysis may be undesirable.",
"   </p>",
"   <p>",
"    Studies examining patients treated in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -era have reported an incidence of required transplant nephrectomy ranging from 20 to 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/10,11,16-21\">",
"     10,11,16-21",
"    </a>",
"    ]. The use of cyclosporine has been associated with a dramatic increase in the incidence of required transplant nephrectomies after the withdrawal of immunosuppressive agents. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of one center's experience reported an incidence of 4 percent (2 of 46 patients) of required nephrectomy for patients administered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , versus 21 percent (13 of 62) for those treated with a regimen that included",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second center found that nephrectomy was required in 63 percent (19 of 30) of patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , versus 27 percent (4 of 11) of those administered azathioprine and prednisone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason for the possible association of graft nephrectomy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    use is unclear. A potential mechanism is the effect of calcineurin inhibition upon immunological tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Indications for nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for transplant nephrectomy are the onset of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complications related to rejection after withdrawal of immunosuppression, and a history of early graft failure (with or without symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complications):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms resulting from rejection and necrosis include graft tenderness, fever, hematuria, localized edema, and occasionally infection. Less fulminant rejection may present with unusual symptoms, such as weight loss, anemia, fatigue, gastrointestinal complaints, neurologic disturbances, and resistance to erythrocyte stimulating agents (ESAs).",
"     </li>",
"     <li>",
"      Patients who have early graft failure (defined as a return to dialysis within one year of transplantation) are much more likely to develop a graft-related complication requiring nephrectomy than are those with late allograft failure, independent of whether immunosuppressive medications are withdrawn. Although such complications may be observed in patients in whom withdrawal is not initiated, the abrupt withdrawal of immunosuppression among those with early graft failure increases the risk of precipitating rejection that requires nephrectomy. In addition, the morbidity and mortality from nephrectomy has improved markedly over the last three decades. These observations have led most centers to adopt a policy of immediate withdrawal of immunosuppression combined with preemptive nephrectomy for patients with early allograft failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, the immediate withdrawal of immunosuppressive agents followed by nephrectomy is less commonly performed for patients with late graft failure (greater than one year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/26\">",
"     26",
"    </a>",
"    ]. The possible indications for transplant nephrectomy in late allograft failure after initiation of dialysis are not clearly defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/27\">",
"     27",
"    </a>",
"    ], but may be considered in patients with signs and symptoms of a chronic inflammatory state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Some clinicians, for example, advocate allograft removal with features of such an inflammatory state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/29\">",
"     29",
"    </a>",
"    ], while others suggest nephrectomy only with symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis based upon the United States Renal Data System suggests that survival is improved after transplant nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/30\">",
"     30",
"    </a>",
"    ]. Among nearly 11,000 dialysis patients with a failed kidney allograft, 32 percent underwent nephrectomy between 1994 and 2004. The relative risk for all-cause death was significantly lower for those with a transplant nephrectomy (adjusted hazard ratio 0.68, 95% CI 0.63 to 0.74). However, it is difficult to generalize these results since the study has several flaws; these include unclear reasons for nephrectomy as well as not defining the comorbid conditions that prevented a nephrectomy. Thus, patients who underwent nephrectomy may have been healthier than those in whom a nephrectomy was not performed. Whether survival is truly improved with nephrectomy requires additional evidence.",
"   </p>",
"   <p>",
"    Although nephrectomy is the conventional approach to removing failed renal allografts, some centers have reported some success with vascular embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Further study is required to delineate the role for this technique in this setting, with some concern related to mortality and the absence of data with hematologic and biochemical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Secondary adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some patients have completed corticosteroid withdrawal at the time of allograft failure, most patients returning to dialysis continue to receive long-term corticosteroid therapy. These patients may be at risk for adrenal insufficiency following steroid withdrawal, although the evidence supporting this is controversial.",
"   </p>",
"   <p>",
"    Dialysis patients with secondary adrenal insufficiency frequently present with subtle findings of isolated glucocorticoid insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These include persistent fever, weakness, fatigability, myalgias, arthralgias, weight loss with subsequent fluid overload because of the lack of adequate ultrafiltration, mild hypercalcemia, and eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients undergo glucocorticoid withdrawal without adverse effects despite an abnormal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    (eg, Cortrosyn stimulation test) or other laboratory evidence of adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .) One study, for example, evaluated 21 renal transplant recipients returning to dialysis; fourteen initially displayed evidence of adrenal suppression as measured by either an ACTH challenge or an inadequate increase in plasma cortisol with insulin administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/35\">",
"     35",
"    </a>",
"    ]. Although the withdrawal of corticosteroids in all patients was associated with few adverse clinical events, 30 percent still had laboratory evidence of adrenal suppression when reassessed at six months.",
"   </p>",
"   <p>",
"    In another series of 13 patients with renal transplant failure who returned to dialysis, seven with a normal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    were immediately removed from corticosteroid therapy, while six with equivocal test results were tapered over one to two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/36\">",
"     36",
"    </a>",
"    ]. These withdrawals occurred without an adverse effect.",
"   </p>",
"   <p>",
"    Thus, although the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    is the \"gold standard\" for diagnosing secondary adrenal insufficiency, a test that predicts the clinical response of patients in the setting of dialysis and concurrent withdrawal of long-term corticosteroids remains to be established. In general, the length of time required to recover normal hypothalamic-pituitary-adrenal function depends upon the degree of suppression; this, in turn, depends upon the dosage and duration of the corticosteroid immunosuppressive therapy. The time varies from a few weeks to as long as nine months or more. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the findings of adrenal insufficiency in this patient population may be subtle, conservative clinical judgment combined with careful laboratory evaluation should be employed. As an example, patients who tolerate corticosteroid withdrawal under relatively non-stressful conditions may require a temporary increase in corticosteroid dosage during periods of stress. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The experience with steroid withdrawal in",
"    <strong>",
"     well-functioning",
"    </strong>",
"    renal transplants demonstrates that gradual corticosteroid withdrawal is not associated with symptomatic adrenal insufficiency. In a randomized trial of withdrawal of corticosteroids over a four-month period, one year after renal transplantation, only 1 of the 49 patients assigned to the withdrawal arm developed symptoms requiring reinstitution of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Implications of residual renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have found that renal function deteriorates rapidly after withdrawal of immunosuppression in both hemodialysis and peritoneal dialysis patients. Thus, a longer taper of immunosuppression may permit the maintenance of some renal function while on dialysis. Although residual renal function is critical for the delivery of adequate doses of dialysis in patients undergoing peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/38\">",
"     38",
"    </a>",
"    ], no studies have adequately addressed its importance in failed renal allografts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sensitization and retransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have noted that patients who have undergone transplant nephrectomy have higher cytotoxic antibody levels than those undergoing dialysis with the allograft still in place:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two series, panel reactive antibody (PRA) levels of greater than 30 percent were more frequent in patients who had undergone transplant nephrectomy (57 versus 33 percent, and 60 versus 30 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report examined 52 patients awaiting renal transplantation, of whom 12 and 14 underwent elective transplant nephrectomy and nephrectomy for symptoms, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients with nephrectomy were more likely to have a PRA of greater than 50 percent than those without nephrectomy (54 versus 15 percent); patients undergoing symptomatic nephrectomy had the highest peak titer PRA.",
"     </li>",
"     <li>",
"      A review of 78 patients with allograft failure after six months and rapid immunosuppression tapering reported an increase in PRA after nephrectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study using a highly sensitive microbead-based single antigen assay, the incidence of donor-specific antibody (DSA) reactivity to HLA-A, HLA-B, and HLA-DRB1 antigen mismatches was significantly lower before than after allograft removal (64 percent versus 87 percent, respectively for HLA-A, B, and 57 percent versus 86 percent, respectively for HLA-DRB1). However, the difference in the incidence of DSA reactivity to HLA-DR51&frasl;DR52&frasl;DR53 and HLA-DQ antigen mismatches was small and statistically insignificant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study that used the microbead assay, at a mean last followup of 538 &plusmn;347 days, the incidence of DSA reactivity was higher among 48 patients who had undergone nephrectomy compared with 21 patients who had not undergone nephrectomy after allograft loss (52 versus 81 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that it is not advisable to routinely perform a transplant nephrectomy after graft failure, and that immediate withdrawal of immunosuppression is associated with an increased need for transplant nephrectomy which is associated with HLA sensitization. It is not clear whether long-term continuation of immunosuppression prevents desensitization in patients who are being considered for retransplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10285280\">",
"    <span class=\"h3\">",
"     Effect of nephrectomy on retransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unresolved issue is whether there might be some benefit for retransplantation from leaving the failed graft in place. Animal models of retransplantation have demonstrated that, to maintain tolerance and accept a second graft, the presence of donor antigen is beneficial. As an example, T cells adoptively transferred to an irradiated host may revert to a normal state of responsiveness in an antigen-free animal as opposed to an animal that bears the donor antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, in a rat heart transplantation model, graftectomy resulted in significantly reduced survival of the second allograft, thereby suggesting a tolerizing effect of residual antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/45\">",
"     45",
"    </a>",
"    ]. Although this hypothesis has not been tested in humans, antigen-specific hyporeactivity induced by pretransplantation blood transfusions suggests that this mechanism is plausible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, however, there appears to be no clinically significant difference in outcome after retransplantation among those with or without nephrectomy in the small, retrospective studies that have addressed this question. In addition, despite the above retrospective findings linking nephrectomy and sensitization, there is no proven causal relationship between nephrectomy and subsequent high PRA levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     METHODS OF WITHDRAWAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled, prospective studies have been performed to determine the best method for",
"    <span class=\"nowrap\">",
"     tapering/withdrawing",
"    </span>",
"    immunosuppression following renal allograft failure. Most transplant centers have center-specific protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41111/abstract/7,47\">",
"     7,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is our approach, which has resulted in a stable nephrectomy rate of approximately 30 percent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We and most transplant centers have adopted a policy of immediate withdrawal of immunosuppression combined with preemptive nephrectomy for patients with early allograft failure, which is defined as failure that occurs less than one year after transplant surgery.",
"     </li>",
"     <li>",
"      We also withdraw immunosuppression with later allograft failure, with no one remaining on any type of immunosuppression for longer than six months from the time of allograft failure. Our standard protocol is to immediately withdraw",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil; we subsequently taper",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      by 1",
"      <span class=\"nowrap\">",
"       mg/month",
"      </span>",
"      until the drug is discontinued, carefully watching for symptoms of adrenal insufficiency.",
"     </li>",
"     <li>",
"      We have a different approach if the patient has continued to produce urine despite allograft failure. In this setting, we prefer to withdraw the anti-metabolite immediately, reduce the calcineurin inhibitor dose to once daily in the morning, and reduce the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose to 5 mg per day; both remaining immunosuppressive agents are tapered slowly over 3 to 6 months. This approach allows the patient to obtain the benefits of the additional solute and water clearance and recover nutritionally; this permits the patient to tolerate a nephrectomy, if necessary, without risking immediate rejection and the need for transplant nephrectomy while balancing the risks of ongoing immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further studies are needed to determine if slower taper of other immunosuppressive agents, such as the calcineurin inhibitors, can reduce the incidence of nephrectomy without untoward side effects in the dialysis population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those who develop symptoms of allograft rejection with withdrawal, we and others administer a five to seven day course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 0.3 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day; patients are subsequently referred for surgery. By comparison, some nephrologists advocate immediate nephrectomy for those with even mild symptoms of rejection after immunosuppressive agent withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rejection and transplant nephrectomy after withdrawal'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reasons to withdraw immunosuppressive medications in dialysis patients with a failed renal transplant are the increased risk of infection, and malignancy if such agents are continued, the adverse effects of long-term corticosteroid therapy, and that dosing of some immunosuppressive agents is difficult in patients with renal failure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Reasons for withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The withdrawal of immunosuppression may be associated with significant complications. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Precipitation of rejection, possibly requiring transplant nephrectomy",
"     </li>",
"     <li>",
"      Secondary adrenal insufficiency",
"     </li>",
"     <li>",
"      Loss of residual renal function",
"     </li>",
"     <li>",
"      Potentially adverse immunologic effects among those pursuing another transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Complications of withdrawal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best method for",
"      <span class=\"nowrap\">",
"       tapering/withdrawing",
"      </span>",
"      immunosuppression following renal allograft failure is unclear, with most transplant centers having center-specific protocols. Our approach is discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Methods of withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     UNOS Registry Data, accessed February, 2009 at www.optn.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/2\">",
"      Langone AJ, Chuang P. The management of the failed renal allograft: an enigma with potential consequences. Semin Dial 2005; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/3\">",
"      Cecka JM. The UNOS Renal Transplant Registry. Clin Transpl 2002; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/4\">",
"      Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/5\">",
"      Gill JS, Abichandani R, Khan S, et al. Opportunities to improve the care of patients with kidney transplant failure. Kidney Int 2002; 61:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/6\">",
"      Knoll G, Muirhead N, Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/7\">",
"      Kendrick EA, Davis CL. Managing the failing allograft. Semin Dial 2005; 18:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/8\">",
"      Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002; 62:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/9\">",
"      Gregoor PJ, Kramer P, Weimar W, van Saase JL. Infections after renal allograft failure in patients with or without low-dose maintenance immunosuppression. Transplantation 1997; 63:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/10\">",
"      Smak Gregoor PJ, Zietse R, van Saase JL, et al. Immunosuppression should be stopped in patients with renal allograft failure. Clin Transplant 2001; 15:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/11\">",
"      Kiberd BA, Belitsky P. The fate of the failed renal transplant. Transplantation 1995; 59:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/12\">",
"      Pham PT, Pham PC. Immunosuppressive management of dialysis patients with recently failed transplants. Semin Dial 2011; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/13\">",
"      van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010; 340:c570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/14\">",
"      Vajdic CM, van Leeuwen MT, Webster AC, et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 2009; 18:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/15\">",
"      Burn DJ, Bates D. Neurology and the kidney. J Neurol Neurosurg Psychiatry 1998; 65:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/16\">",
"      Madore F, H&eacute;bert MJ, Leblanc M, et al. Determinants of late allograft nephrectomy. Clin Nephrol 1995; 44:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/17\">",
"      Thomas PP, Jacob CK, Kirubakaran MG, et al. Indication for routine allograft nephrectomy in cases of irreversible rejection. Transplantation 1989; 48:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/18\">",
"      DiSesa VJ, Tilney NL. Conservative management of the failed renal allograft: indications for transplant nephrectomy. Curr Surg 1982; 39:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/19\">",
"      Freier DT, Haines RF, Rosenzweig J, et al. Sequential renal transplants: some surgical and immunological implications on management of the first homograft. Surgery 1976; 79:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/20\">",
"      Noel C, Hazzan M, Boukelmoune M, et al. Indication for allograft nephrectomy after irreversible rejection: is there an ideal delay? Transplant Proc 1997; 29:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/21\">",
"      Gourlay, WA, Patterson, R, Gill, J, et al. Influence of transplant nephrectomy on panel reactive antibody titer and waiting time for second kidney transplants (abstract). Transplantation 1999; 67:S169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/22\">",
"      Matzinger P. Graft tolerance: a duel of two signals. Nat Med 1999; 5:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/23\">",
"      Vanrenterghem Y, Khamis S. The management of the failed renal allograft. Nephrol Dial Transplant 1996; 11:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/24\">",
"      Roberts CS, LaFond J, Fitts CT, et al. New patterns of transplant nephrectomy in the cyclosporine era. J Am Coll Surg 1994; 178:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/25\">",
"      O'Sullivan DC, Murphy DM, McLean P, Donovan MG. Transplant nephrectomy over 20 years: factors involved in associated morbidity and mortality. J Urol 1994; 151:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/26\">",
"      Johnston O, Rose C, Landsberg D, et al. Nephrectomy after transplant failure: current practice and outcomes. Am J Transplant 2007; 7:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/27\">",
"      Bia, M. Indications for nephrectomy of a failed transplant. Semin Dial 1998; 11:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/28\">",
"      L&oacute;pez-G&oacute;mez JM, P&eacute;rez-Flores I, Jofr&eacute; R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/29\">",
"      Ayus JC, Achinger SG. At the peril of dialysis patients: ignoring the failed transplant. Semin Dial 2005; 18:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/30\">",
"      Ayus JC, Achinger SG, Lee S, et al. Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol 2010; 21:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/31\">",
"      Delgado P, Diaz F, Gonzalez A, et al. Intolerance syndrome in failed renal allografts: incidence and efficacy of percutaneous embolization. Am J Kidney Dis 2005; 46:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/32\">",
"      Cofan F, Real MI, Vilardell J, et al. Percutaneous renal artery embolisation of non-functioning renal allografts with clinical intolerance. Transpl Int 2002; 15:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/33\">",
"      Verresen L, Vanrenterghem Y, Waer M, et al. Corticosteroid withdrawal syndrome in dialysis patients. Nephrol Dial Transplant 1988; 3:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/34\">",
"      Sever MS, T&uuml;rkmen A, Yildiz A, et al. Fever in dialysis patients with recently rejected renal allografts. Int J Artif Organs 1998; 21:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/35\">",
"      Rodger RS, Watson MJ, Sellars L, et al. Hypothalamic-pituitary-adrenocortical suppression and recovery in renal transplant patients returning to maintenance dialysis. Q J Med 1986; 61:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/36\">",
"      Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/37\">",
"      Ratcliffe PJ, Dudley CR, Higgins RM, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/38\">",
"      Lameire NH. The impact of residual renal function on the adequacy of peritoneal dialysis. Nephron 1997; 77:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/39\">",
"      Sumrani N, Delaney V, Hong JH, et al. The influence of nephrectomy of the primary allograft on retransplant graft outcome in the cyclosporine era. Transplantation 1992; 53:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/40\">",
"      Douzdjian V, Rice JC, Carson RW, et al. Renal retransplants: effect of primary allograft nephrectomy on early function, acute rejection and outcome. Clin Transplant 1996; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/41\">",
"      Khakhar AK, Shahinian VB, House AA, et al. The impact of allograft nephrectomy on percent panel reactive antibody and clinical outcome. Transplant Proc 2003; 35:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/42\">",
"      Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 2010; 22:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/43\">",
"      Del Bello A, Congy-Jolivet N, Sallusto F, et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 2012; 7:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/44\">",
"      Ramsdell F, Fowlkes BJ. Maintenance of in vivo tolerance by persistence of antigen. Science 1992; 257:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/45\">",
"      Nishinaka H, Nakafusa Y, Hirano T, et al. Graft persistence effectively induces and maintains donor-specific unresponsiveness. J Surg Res 1997; 68:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/46\">",
"      Jackson A, McSherry C, Butters K, et al. Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity. Hum Immunol 1997; 55:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41111/abstract/47\">",
"      Bennett WM. The failed renal transplant: in or out? Semin Dial 2005; 18:188.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7320 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-C85CA16B23-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41111=[""].join("\n");
var outline_f40_9_41111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REASONS FOR WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased risk of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4788554\">",
"      Increased risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complications of corticosteroid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Altered drug dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPLICATIONS OF WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rejection and transplant nephrectomy after withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Indications for nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Secondary adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Implications of residual renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sensitization and retransplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10285280\">",
"      - Effect of nephrectomy on retransplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      METHODS OF WITHDRAWAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7320|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/19/17712\" title=\"diagnostic image 1\">",
"      Rejection drug withdrawal CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_9_41112="Heparin necrosis ulcers";
var content_f40_9_41112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63715%7EDERM%2F71259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63715%7EDERM%2F71259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Heparin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Necrotic ulcers are present in this patient with heparin necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Heparin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Purpuric lesions and skin necrosis are present in this patient with heparin necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41112=[""].join("\n");
var outline_f40_9_41112=null;
var title_f40_9_41113="Clinical features and diagnosis of coronary heart disease in women";
var content_f40_9_41113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of coronary heart disease in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41113/contributors\">",
"     Pamela S Douglas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41113/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41113/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41113/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41113/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/9/41113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular diseases are the most common cause of death and disability in women in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although there has been a reduction in the death rate from coronary heart disease (CHD) since 1980 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/3\">",
"     3",
"    </a>",
"    ], CHD accounted for 35 percent of all-cause mortality in women in 1995 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/2\">",
"     2",
"    </a>",
"    ] and 23 percent in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/4\">",
"     4",
"    </a>",
"    ]. Between the ages of 45 to 64, one in nine women develops symptoms of some form of cardiovascular disease. After age 65, the ratio climbs to one in three women, according to the National Center for Health Statistics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are significant differences between men and women in the epidemiology, diagnosis, treatment, and prognosis of CHD that should be taken into account in the care of women with known or suspected disease. Furthermore, most available data suggest that women are not referred as often as men for appropriate diagnostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapeutic procedures, despite similar clinical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/6-12\">",
"     6-12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnostic testing for suspected CHD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of CHD in women will be reviewed here. The epidemiology and prognosis of CHD, management of CHD in women, and the problem of CHD in young women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44361?source=see_link\">",
"     \"Epidemiology of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=see_link\">",
"     \"Management of coronary heart disease in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with CHD are generally about 10 years older than men at the time of presentation and carry a greater burden of risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Women may not identify their initial symptoms as an expression of heart disease and therefore may not seek medical advice promptly and practitioners may not evaluate symptoms that represent myocardial ischemia as early in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although women are generally older than men at presentation, women younger than age 45 years also develop CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/17\">",
"     17",
"    </a>",
"    ] and have a worse prognosis than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/18\">",
"     18",
"    </a>",
"    ]. The first presentation of CHD may be chest pain, myocardial infarction, heart failure, or sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link\">",
"     \"Coronary heart disease and myocardial infarction in young men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of importance, the Framingham Risk Estimation underestimates risk in women with a family history of early heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are more likely to initially present with symptoms such as chest pain than a more clearly defined event such as a myocardial infarction. In a 26-year follow-up from the Framingham Study, for example, angina was uncomplicated in 80 percent of women, whereas it evolved out of infarction in 66 percent of men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in men, the quality of chest pain is an important predictor of angiographic disease in women (",
"    <a class=\"graphic graphic_table graphicRef53433 graphicRef64463 \" href=\"mobipreview.htm?18/57/19357\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Women are less likely than men to have typical angina (28 versus 55 percent in a review of over 3100 patients undergoing exercise stress testing) and are more likely to have atypical or non-anginal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differences between women and men were illustrated in a review of 38 women and 94 men who, in a prospective study of 907 patients undergoing exercise stress testing with perfusion imaging, had both angina and imaging evidence of ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/23\">",
"     23",
"    </a>",
"    ]. Women rated their chest pain as more intense, used different terms to describe the pain (more often sharp and burning), had more symptoms unrelated to pain, and more frequently had pain and other sensations in the neck and throat. Another report identified fatigue and dyspnea as frequent complaints among women; chest pain often radiated to the back or jaw [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another factor important in the interpretation of symptoms in women is the greater likelihood of their being induced by rest, sleep, and mental stress, in addition to or instead of physical exertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, a previous history of an anxiety disorder is associated with a lower risk of significant angiographic CHD in women (odds ratio 2.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/25\">",
"     25",
"    </a>",
"    ]. Psychosocial factors are also important, as women drastically underestimate their own risk of CHD, and physicians' estimates are colored by patient affect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due at least in part to the above observations, women who present to the emergency department with new onset chest pain are approached and diagnosed less aggressively than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared to men, women are less likely to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Undergo an electrocardiogram [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/8\">",
"       8",
"      </a>",
"      ], cardiac monitoring, or cardiac enzyme measurements",
"     </li>",
"     <li>",
"      Receive a cardiology consult",
"     </li>",
"     <li>",
"      Be admitted to a coronary care or step down unit",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, such women are more likely to receive controlled substances and anxiolytics in the emergency department, suggesting that they were being treated for psychiatric or psychosomatic complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction (MI) in women may go unrecognized, particularly at younger ages and when compared to men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies support and attempt to explain this observation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency of unrecognized MI was illustrated in a report from Iceland in which 13,000 women were followed for 29 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. The incidence of myocardial infarction on the ECG increased from 1.3 per 1000 at age 35 to 60 per 1000 at age 75; the proportion that were unrecognized was higher in the younger women (41 versus 24 percent).",
"     </li>",
"     <li>",
"      A higher proportion of silent Q wave infarctions in older women was noted in a report from the HERS trial, which evaluated the efficacy of hormone replacement therapy in 2763 postmenopausal women with known CHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/28\">",
"       28",
"      </a>",
"      ]. During a four year follow-up, 9.3 percent had ECG evidence of an MI that was unrecognized clinically in 46 percent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44361?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology of coronary heart disease\", section on 'Silent myocardial ischemia and infarction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presenting symptoms of MI in women differ from those in men, which may in part explain the greater delays in both seeking and receiving care. In one study comparing 550 women with 610 men, all with an acute MI, women were more likely to experience pain in the neck, jaw, or back, and nausea in addition to chest pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report of 515 women with an acute MI, acute chest pain was absent in 43 percent; the most common presenting symptoms were shortness of breath (58 percent), weakness (55 percent), and fatigue (43 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/30\">",
"       30",
"      </a>",
"      ]. In addition, only 30 percent experienced prodromal chest pain. The most frequent prodromal symptoms (symptoms present more than one month) were unusual fatigue (71 percent), sleep disturbance (48 percent), and shortness of breath (42 percent).",
"     </li>",
"     <li>",
"      The observation that women with acute MI often present without chest pain found in the study directly above was also noted in a study of over 1,000,000 women and men in the National Registry of Myocardial Infarction (United States) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/31\">",
"       31",
"      </a>",
"      ].The proportion of MI patients who presented without chest pain was significantly higher for women than men (42.0 versus 30.7 percent). However, there was a significant interaction between age and sex such that there was a larger sex difference in younger than older patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have specifically evaluated the outcomes in women with a non-ST elevation ACS (unstable angina or non-ST elevation [non-Q wave] MI). In the GUSTO IIb trial, which evaluated 12,142 patients presenting with an acute coronary syndrome, women were less likely to have ST segment elevation (27 versus 37 percent for men) and, among those without ST segment elevation, women were less likely to have an MI (37 versus 48 percent).",
"   </p>",
"   <p>",
"    The optimal approach to accurate assessment of risk in women with a non-ST elevation ACS may differ from that in men. This was suggested by an analysis from TACTICS-TIMI 18, which found that women were more likely to have elevations of hs-CRP and BNP, and less likely to have elevations of troponins and CK-MB, than men, despite similar levels of risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/32\">",
"     32",
"    </a>",
"    ]. Further, when a multimarker approach incorporating hs-CRP, BNP, and troponins was used, women with any positive marker benefited from an invasive strategy, while those with no positive markers benefited from a conservative strategy. In contrast, men benefited from an invasive strategy when there was biomarker positivity, but there was no difference in benefit according to strategy if biomarkers were negative. Thus, women with unstable angina without positive biomarkers should be treated conservatively, without early catheterization or use of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29257?source=see_link&amp;anchor=H15#H15\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\", section on 'Effect in women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to either typical or atypical chest pain, CHD can present as heart failure or sudden cardiac death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with CHD more frequently have or develop symptomatic heart failure (HF) than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This appears to be due at least in part to a greater frequency of diastolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/34\">",
"     34",
"    </a>",
"    ]. Why this might occur is not known, but is postulated to be related to a greater prevalence of hypertensive heart disease and hypertrophy in women.",
"   </p>",
"   <p>",
"    Risk factors for HF in women with CHD were examined in an analysis from the HERS trial of 2391 women with established coronary disease who had no HF at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/35\">",
"     35",
"    </a>",
"    ]. At a mean of six years, 237 women (10 percent) developed HF. Significant risk factors included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Atrial fibrillation",
"     </li>",
"     <li>",
"      MI",
"     </li>",
"     <li>",
"      Renal dysfunction (creatinine clearance &lt;40",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"     </li>",
"     <li>",
"      Hypertension (systolic blood pressure &gt;120 mmHg)",
"     </li>",
"     <li>",
"      Current smoking",
"     </li>",
"     <li>",
"      Obesity (body mass index &gt;35",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      Left bundle branch block on electrocardiogram",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy on electrocardiogram",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diabetes was the variable associated with the greatest increase in HF risk (adjusted hazard ratio 3.1). Women with diabetes and at least three other risk factors had an annual HF incidence of 8.2 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sudden cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 38-year follow-up from the Framingham Heart study evaluated the incidence of sudden cardiac death (SCD) in women compared to men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/36\">",
"     36",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women had a lower SCD rate than men at all ages and at any level of multivariate risk (",
"      <a class=\"graphic graphic_figure graphicRef59028 \" href=\"mobipreview.htm?18/4/18509\">",
"       figure 1",
"      </a>",
"      ); the risk of sudden death among women with CHD was one-half that of men with CHD and accounted for a smaller proportion of coronary deaths (37 versus 56 percent).",
"     </li>",
"     <li>",
"      A higher fraction of sudden deaths in women occurred in the absence of prior overt CHD (63 versus 44 percent in men). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=see_link\">",
"       \"Pathophysiology and etiology of sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of heart failure increased overall mortality and the incidence of SCD; however, among patients with heart failure, the absolute risk in women was only one-third that of men (",
"      <a class=\"graphic graphic_figure graphicRef58658 \" href=\"mobipreview.htm?31/17/32029\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Phobic anxiety is associated with an increased risk of SCD in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/37\">",
"     37",
"    </a>",
"    ]. Some, but not all, of this risk can be ascribed to CHD risk factors associated with phobic anxiety such as diabetes, hypertension, and elevated serum cholesterol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING FOR SUSPECTED CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a woman presenting with symptoms of chest pain and suspected CHD is similar to that for men and often includes some form of noninvasive testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Noninvasive testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following tests are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treadmill exercise testing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"       \"Stress testing for the diagnosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radionuclide myocardial perfusion imaging with either exercise or pharmacologic stress. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=see_link\">",
"       \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43081?source=see_link\">",
"       \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stress echocardiography with either exercise or pharmacologic stress. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coronary angiography with cardiac computed tomography. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=see_link\">",
"       \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coronary artery calcium scoring (CCTA). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link\">",
"       \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these tests is imperfect in its ability to accurately diagnose CHD (see individual topic reviews). The following points need to be kept in mind when considering a noninvasive test in women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treadmill exercise testing has a higher false-positive rate in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/38\">",
"       38",
"      </a>",
"      ]. This is in part due to a lower prevalence of CHD in women in the populations studied (Bayesian factors). The diagnostic accuracy in women is also lower due to older age at presentation with the attendant higher frequency of comorbidities and lower exercise capacity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/4\">",
"       4",
"      </a>",
"      ]. Other explanations for the sex-related differences have included hormonal medication and autonomic influences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/4\">",
"       4",
"      </a>",
"      ]. Nevertheless, exercise stress provides valuable information regarding reproducibility of symptoms, exercise capacity and longevity, and is the preferred mode of stress in women, with or without imaging. Of note, women have a lower functional capacity than men, usually achieving a maximal workload that is 2 METs less than for men.",
"     </li>",
"     <li>",
"      The sensitivity and specificity of these tests are suboptimal. In a meta-analysis, which evaluated 19 studies of women who underwent exercise ECG testing (five exercise thallium and three of exercise echocardiography) and coronary angiography, the sensitivity and specificity for CHD of exercise ECG stress testing, exercise thallium, and exercise echocardiography were 61 and 70 percent, 78 and 64 percent, and 86 and 79 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/39\">",
"       39",
"      </a>",
"      ]. These values are similar to those in men for stress echo and nuclear, but lower for stress ECG.",
"     </li>",
"     <li>",
"      None of the stress tests is without sources of artifact. All require adequate stress for optimal accuracy, whether pharmacologic or exercise. Thus, a negative exercise test in a patient with poor exercise tolerance may be inconclusive.",
"     </li>",
"     <li>",
"      Radiation exposure from CCTA and radionuclide tests have not been convincingly shown to be harmful, but are best avoided in young women, as breast tissue is included in the radiation field. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14376?source=see_link\">",
"       \"Radiation dose and risk of malignancy from cardiovascular imaging\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     For episodic chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who present with episodic chest pain need to be evaluated for CHD. The likelihood of CHD is based in part upon the character of the presenting symptoms (eg, typical versus atypical angina) and the presence or absence of coronary risk factors. The risk assessment must be sex specific because the risk factors themselves, as well as their relative importance, may differ between women and men. In particular, hormonal status, diabetes, smoking, and a family history of premature CHD appear to be more important in women. Of note, the American Heart Association guidelines for primary prevention in women suggest that using a life time likelihood of CAD is preferred in women, rather than a more conventional 10-year Framingham risk calculation, as the latter often underestimates risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, local expertise and test availability should dictate noninvasive test selection, given the lack of clearly identifiable differences in accuracy. One sequential approach is as follows and is generally in accord with that in the 2012",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline for the diagnosis and management of patients with stable ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This 2012 guideline does not specify separate diagnostic approaches for women and men.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation of a woman with suspected CHD begins with a careful history and physical examination, laboratory work and assessment of risk. If the patient is determined to be at intermediate risk, a stress test may be ordered. The exact choice of test will depend on a variety of clinical factors such as patient risk, ability to exercise, body habitus, prior test information for comparison and non-clinical factors such as local test availability and expertise. If an exercise treadmill is chosen, the stress is adequate (maximal), the ECG interpretable, and the test negative, no further evaluation is necessary.",
"     </li>",
"     <li>",
"      Women with a positive test or a negative submaximal test should undergo additional testing, which may include stress echocardiography or stress nuclear imaging (ideally with a technetium perfusion radiotracer), cardiac CTA, or diagnostic cath. In particular, patients with a high probability positive test should go on to coronary angiography if they are candidates for revascularization. Such women have a worse outcome if they are not further evaluated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal role of coronary calcium scoring or measurement of carotid intimal medial thickness in the evaluation of stable symptoms is unclear at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H10122160#H10122160\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Arterial intima-media thickness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     After non-ST elevation ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early exercise testing in women after a non-ST elevation ACS can be useful in those who have not had a coronary angiogram for establishing the presence of coronary disease and for risk stratification and prognosis. The majority of patients who have undergone coronary angiography do not need further risk assessment, although testing may be indicated once the acute phase of ACS is resolved to evaluate the possible significance of lesions in vessels other than the infarct related artery.",
"   </p>",
"   <p>",
"    If testing is indicated, findings on the exercise test that independently predict future cardiac events are low maximal workload, the number of leads with &ge;0.1 mV ST segment depression, and maximal rate-pressure product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-risk patients have at least two of these three criteria, intermediate-risk patients have one criterion, and low-risk patients lack all three criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/47\">",
"     47",
"    </a>",
"    ]. However, as noted above, women have a high percentage of false-positive exercise tests, which might make the test less reliable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/38\">",
"     38",
"    </a>",
"    ]. This issue was addressed in a study of 395 women with unstable angina entered into the FRISC trial who were followed for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/47\">",
"     47",
"    </a>",
"    ]. Based upon the exercise test results, low-, intermediate-, and high-risk groups were identified with event rates of cardiac death or myocardial infarction of 1, 9, and 19 percent, respectively. The results were the same as those observed for 778 men in the trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for diagnostic cardiac catheterization and coronary angiography are similar for women and men. Recommendations for invasive testing are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link&amp;anchor=H94289721#H94289721\">",
"     \"Overview of the care of patients with stable ischemic heart disease\", section on 'Coronary angiography and revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of significant coronary disease found at the time of angiography is lower in women than men presenting with chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/33,48,49\">",
"     33,48,49",
"    </a>",
"    ]. The magnitude of this difference was illustrated in a report of 886 patients referred for angiographic evaluation of presumed angina, 23 percent of whom were women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/48\">",
"     48",
"    </a>",
"    ]. Normal coronary arteries were much more common in women (41 versus 8 percent in men).",
"   </p>",
"   <p>",
"    A higher rate of absence of significant coronary stenoses has also been noted in women with a non-ST elevation acute coronary syndrome (unstable angina or non-ST elevation myocardial infarction). In different clinical trials, 12 to 14 percent of such patients have, on coronary angiography, either normal vessels or no vessel with &ge;50 to 60 percent stenosis. This appears to be more common in women (17 versus 9 percent in men in one trial) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Possible mechanisms for the absence of significant coronary disease in these patients include rapid clot lysis, vasospasm, and coronary microvascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28505?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\", section on 'Absence of significant coronary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Gender bias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have documented gender-based differences in utilization rates of coronary angiography and revascularization, even among those with an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/7,43,52-58\">",
"     7,43,52-58",
"    </a>",
"    ]. These differences reflect physicians' failure to refer women with positive exercise tests for subsequent testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/57\">",
"     57",
"    </a>",
"    ], leading to a poorer outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/43\">",
"     43",
"    </a>",
"    ]. In one report, for example, women with a positive exercise test were more likely to have no further cardiac evaluation than men (62 versus 38 percent), a difference that, at three year follow-up, was associated with a higher incidence of MI or death in women (14.3 versus 6 percent per year in men) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/43\">",
"     43",
"    </a>",
"    ]. All events occurred in nonrevascularized individuals.",
"   </p>",
"   <p>",
"    Other studies have not found a difference in catheterization rates between men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. However, closer examination of these reports reveals an over referral of low risk men (based upon clinical risk stratification) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/59\">",
"     59",
"    </a>",
"    ], and a near equal rate of catheterization following myocardial infarction when the procedure was performed for the treatment, not diagnosis, of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/60\">",
"     60",
"    </a>",
"    ]. In a review of over 3000 patients (33 percent women) who underwent exercise radionuclide imaging, referral rates for men and women were comparable when stratified by the amount of abnormally perfused myocardium detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/62\">",
"     62",
"    </a>",
"    ]. However, among patients with an abnormal scan, the subsequent cardiac event rate was higher for women than men (17.5 versus 6.3 percent), indicating that women were under referred for comparable degrees of risk.",
"   </p>",
"   <p>",
"    A separate issue is whether gender bias affects the likelihood of revascularization after cardiac catheterization. In a review of over 21,000 patients, women had equal access to revascularization after adjustment for clinical variables (eg, age, diabetes, heart failure, renal insufficiency) and coronary variables (eg, extent of disease, left ventricular ejection fraction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=see_link\">",
"     \"Management of coronary heart disease in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Non-CHD causes of chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three non-CHD causes of chest pain may be found at the time of catheterization: cardiac syndrome X, stress-induced cardiomyopathy, and spontaneous coronary artery dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cardiac syndrome X or coronary microvascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary microvascular dysfunction is present in 20 to 50 percent of women with chest pain and normal coronary arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Stress-induced cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon but increasingly reported cause of an acute, usually ST elevation coronary syndrome occurring in the absence of critical coronary artery disease is stress-induced cardiomyopathy, also called transient left ventricular apical ballooning, takotsubo cardiomyopathy, and broken heart syndrome. This disorder is typically precipitated by intense psychologic stress and primarily occurs in postmenopausal women. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Spontaneous coronary artery dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous coronary artery dissection is a rare cause of acute myocardial infarction (MI) that is more common in younger patients and in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/69\">",
"     69",
"    </a>",
"    ]. The underlying mechanism is unknown, but an intimal tear or primary disruption with bleeding of vasa vasorum and intramedial hemorrhage have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/70\">",
"     70",
"    </a>",
"    ]. In pregnant women, dissection may be a consequence of increased hemodynamic stress or of hormonal effects on the arterial wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=see_link&amp;anchor=H4171842#H4171842\">",
"     \"Acquired heart disease and pregnancy\", section on 'Myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients presenting with this entity typically do not have risk factors for coronary heart disease. Histologically, an inflammatory reaction in the adventitia has been described, suggestive of periarteritis. However, this inflammatory response may be reactive rather than causative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2012 single-center report (Mayo Clinic) contains the largest series of patients (87 individuals from over three decades) with spontaneous coronary artery dissection and no associated coronary artery atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/72\">",
"     72",
"    </a>",
"    ]. The diagnosis was made by the finding of a dissection plane on angiography. This registry report noted the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age was 43 years and 82 percent were women.",
"     </li>",
"     <li>",
"      Extreme exertion preceded the event in 7 of 16 men and 2 of 71 women; postpartum status was present in 13 of 71 women (mean postpartum period 38 days).",
"     </li>",
"     <li>",
"      ST-elevation myocardial infarction (STEMI) was present in 49 percent and non-ST elevation in 44 percent of patients on presentation. Chest pain was present in 91 percent and life-threatening ventricular arrhythmias in 14 percent.",
"     </li>",
"     <li>",
"      The left anterior descending coronary artery was the most frequently affected vessel and multivessel dissection was found in 23 percent.",
"     </li>",
"     <li>",
"      The in-hospital prognosis was generally good for those managed either conservatively or with coronary artery bypass grafting (CABG), while the short-term outcome was less favorable in those managed with percutaneous coronary intervention (PCI). The authors speculated that this poorer outcome with PCI might have been attributable to the use of balloon angioplasty without stenting in patients presenting before the use of stents was common.",
"     </li>",
"     <li>",
"      The 10-year recurrence rate was 29.4 percent. The estimated 10-year rate of death, heart failure, myocardial infarction, or dissection recurrence was 47 percent (median follow-up of 47 months).",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia of the renal arteries was found in 8 of 16 femoral angiograms. Two patients were noted to have carotid artery dissection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are generally consistent with earlier reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/71,73-75\">",
"     71,73-75",
"    </a>",
"    ]. However, many of these included patients with associated significant atherosclerotic coronary artery disease, which could potentially influence epidemiology, clinical presentation, or prognosis.",
"   </p>",
"   <p>",
"    Spontaneous coronary dissection should be considered in any young patient, especially any young woman without a previous cardiac history or CHD risk factors, who presents with cardiac arrest or an acute coronary syndrome. The optimal management of spontaneous coronary artery dissection is uncertain, in part because of the limited clinical experience.",
"   </p>",
"   <p>",
"    Emergent coronary angiography followed by PCI or CABG is likely to offer the best prospect of survival. Fibrinolytic therapy may also be successful for patients with STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/69\">",
"     69",
"    </a>",
"    ], but extension of the dissection is possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41113/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/54/7012?source=see_link\">",
"       \"Patient information: Coronary heart disease in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular diseases are the most common cause of death and disability in women in the United States. Important differences between women and men in the presentation of CHD may make it more difficult to establish the diagnosis in women (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical presentation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women generally present about 10 years later than men and with a greater risk-factor burden.",
"     </li>",
"     <li>",
"      Women are less likely than men to have typical angina.",
"     </li>",
"     <li>",
"      Women who present to the emergency department with new onset chest pain are approached and diagnosed less aggressively than men.",
"     </li>",
"     <li>",
"      Women are more likely to initially present with chest pain than a more clearly defined event such as a myocardial infarction.",
"     </li>",
"     <li>",
"      The symptoms of MI in women may differ slightly from those in men. Many cases of myocardial infarction (MI) in women go unrecognized, particularly at younger ages or in patients with diabetes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'MI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The process of establishing the diagnosis of CHD in women is similar to that in men, but several points need to be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treadmill exercise testing has a higher false-positive rate in women, while stress imaging appears to have similar accuracy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Noninvasive testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of significant coronary disease found at the time of angiography is lower in women than men presenting with chest pain.",
"     </li>",
"     <li>",
"      Women with chest pain and no evidence of atherosclerotic coronary artery disease on coronary angiography may have cardiac syndrome X or microvascular disease, or far more rarely, takotsubo cardiomyopathy or coronary dissection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Non-CHD causes of chest pain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/1\">",
"      Eaker ED, Chesebro JH, Sacks FM, et al. Cardiovascular disease in women. Circulation 1993; 88:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/2\">",
"      Mosca L, Manson JE, Sutherland SE, et al. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1997; 96:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/3\">",
"      Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/4\">",
"      Stangl V, Witzel V, Baumann G, Stangl K. Current diagnostic concepts to detect coronary artery disease in women. Eur Heart J 2008; 29:707.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.americanheart.org/downloadable/heart/123783441267009Heart%20and%20Stroke%20Update.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/6\">",
"      Lehmann JB, Wehner PS, Lehmann CU, Savory LM. Gender bias in the evaluation of chest pain in the emergency department. Am J Cardiol 1996; 77:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/7\">",
"      Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol 1999; 84:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/8\">",
"      Arnold AL, Milner KA, Vaccarino V. Sex and race differences in electrocardiogram use (the National Hospital Ambulatory Medical Care Survey). Am J Cardiol 2001; 88:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/9\">",
"      Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation 2005; 111:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/10\">",
"      Seils DM, Friedman JY, Schulman KA. Sex differences in the referral process for invasive cardiac procedures. J Am Med Womens Assoc 2001; 56:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/11\">",
"      Polk DM, Naqvi TZ. Cardiovascular disease in women: sex differences in presentation, risk factors, and evaluation. Curr Cardiol Rep 2005; 7:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/12\">",
"      Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006; 47:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/13\">",
"      Orencia A, Bailey K, Yawn BP, Kottke TE. Effect of gender on long-term outcome of angina pectoris and myocardial infarction/sudden unexpected death. JAMA 1993; 269:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/14\">",
"      Kannel WB, Vokonas PS. Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women. Ann Epidemiol 1992; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/15\">",
"      Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/16\">",
"      Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/17\">",
"      Wenger NK. You've come a long way, baby: cardiovascular health and disease in women: problems and prospects. Circulation 2004; 109:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/18\">",
"      Alter DA, Naylor CD, Austin PC, Tu JV. Biology or bias: practice patterns and long-term outcomes for men and women with acute myocardial infarction. J Am Coll Cardiol 2002; 39:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/19\">",
"      Michos ED, Vasamreddy CR, Becker DM, et al. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J 2005; 150:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/20\">",
"      Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979; 300:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/21\">",
"      Weiner DA, Ryan TJ, McCabe CH, et al. Exercise stress testing. Correlations among history of angina, ST-segment response and prevalence of coronary-artery disease in the Coronary Artery Surgery Study (CASS). N Engl J Med 1979; 301:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/22\">",
"      Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998; 32:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/23\">",
"      D'Antono B, Dupuis G, Fortin C, et al. Angina symptoms in men and women with stable coronary artery disease and evidence of exercise-induced myocardial perfusion defects. Am Heart J 2006; 151:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/24\">",
"      Pepine CJ, Abrams J, Marks RG, et al. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol 1994; 74:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/25\">",
"      Rutledge T, Reis SE, Olson M, et al. History of anxiety disorders is associated with a decreased likelihood of angiographic coronary artery disease in women with chest pain: the WISE study. J Am Coll Cardiol 2001; 37:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/26\">",
"      Birdwell BG, Herbers JE, Kroenke K. Evaluating chest pain. The patient's presentation style alters the physician's diagnostic approach. Arch Intern Med 1993; 153:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/27\">",
"      J&oacute;nsd&oacute;ttir LS, Sigfusson N, Sigvaldason H, Thorgeirsson G. Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study. Eur Heart J 1998; 19:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/28\">",
"      Shlipak MG, Elmouchi DA, Herrington DM, et al. The incidence of unrecognized myocardial infarction in women with coronary heart disease. Ann Intern Med 2001; 134:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/29\">",
"      Goldberg RJ, O'Donnell C, Yarzebski J, et al. Sex differences in symptom presentation associated with acute myocardial infarction: a population-based perspective. Am Heart J 1998; 136:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/30\">",
"      McSweeney JC, Cody M, O'Sullivan P, et al. Women's early warning symptoms of acute myocardial infarction. Circulation 2003; 108:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/31\">",
"      Canto JG, Rogers WJ, Goldberg RJ, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA 2012; 307:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/32\">",
"      Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 2004; 109:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/33\">",
"      Gurevitz O, Jonas M, Boyko V, et al. Clinical profile and long-term prognosis of women &lt; or = 50 years of age referred for coronary angiography for evaluation of chest pain. Am J Cardiol 2000; 85:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/34\">",
"      Mendes LA, Davidoff R, Cupples LA, et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997; 134:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/35\">",
"      Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary disease. Circulation 2004; 110:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/36\">",
"      Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998; 136:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/37\">",
"      Albert CM, Chae CU, Rexrode KM, et al. Phobic anxiety and risk of coronary heart disease and sudden cardiac death among women. Circulation 2005; 111:480.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons, RF. Exercise ECG testing with and without radionuclide studies. In: Cardiovascular Health and Disease in Women, Wenger, NK, Speroff, L, Packard, B (Eds), Le Jacq Communications, Inc, Connecticut 1993. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/39\">",
"      Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999; 83:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/40\">",
"      Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004; 43:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/41\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/42\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/43\">",
"      Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med 1994; 120:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/44\">",
"      Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol 2006; 48:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/45\">",
"      Al-Khalili F, Svane B, Wamala SP, et al. Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study. Am Heart J 2000; 139:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/46\">",
"      Al-Khalili F, Wamala SP, Orth-Gom&eacute;r K, Schenck-Gustafsson K. Prognostic value of exercise testing in women after acute coronary syndromes (The Stockholm Female Coronary Risk Study). Am J Cardiol 2000; 86:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/47\">",
"      S&auml;fstr&ouml;m K, Lindahl B, Swahn E. Risk stratification in unstable coronary artery disease--exercise test and troponin T from a gender perspective. FRISC-Study Group. Fragmin during InStability in Coronary artery disease. J Am Coll Cardiol 2000; 35:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/48\">",
"      Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ 1994; 308:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/49\">",
"      Merz CN, Kelsey SF, Pepine CJ, et al. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol 1999; 33:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/50\">",
"      Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002; 288:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/51\">",
"      Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 2000; 102:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/52\">",
"      Roger VL, Farkouh ME, Weston SA, et al. Sex differences in evaluation and outcome of unstable angina. JAMA 2000; 283:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/53\">",
"      Gan SC, Beaver SK, Houck PM, et al. Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med 2000; 343:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/54\">",
"      Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991; 325:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/55\">",
"      Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med 1991; 325:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/56\">",
"      Bearden D, Allman R, McDonald R, et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program. J Am Geriatr Soc 1994; 42:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/57\">",
"      Tobin JN, Wassertheil-Smoller S, Wexler JP, et al. Sex bias in considering coronary bypass surgery. Ann Intern Med 1987; 107:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/58\">",
"      Rathore SS, Chen J, Wang Y, et al. Sex differences in cardiac catheterization: the role of physician gender. JAMA 2001; 286:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/59\">",
"      Bickell NA, Pieper KS, Lee KL, et al. Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med 1992; 116:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/60\">",
"      Krumholz HM, Douglas PS, Lauer MS, Pasternak RC. Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: is there evidence for a gender bias? Ann Intern Med 1992; 116:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/61\">",
"      Mark DB, Shaw LK, DeLong ER, et al. Absence of sex bias in the referral of patients for cardiac catheterization. N Engl J Med 1994; 330:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/62\">",
"      Hachamovitch R, Berman DS, Kiat H, et al. Gender-related differences in clinical management after exercise nuclear testing. J Am Coll Cardiol 1995; 26:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/63\">",
"      Ghali WA, Faris PD, Galbraith PD, et al. Sex differences in access to coronary revascularization after cardiac catheterization: importance of detailed clinical data. Ann Intern Med 2002; 136:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/64\">",
"      Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000; 342:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/65\">",
"      Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/66\">",
"      Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001; 141:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/67\">",
"      Masci PG, Laclaustra M, Lara JG, Kaski JC. Brachial artery flow-mediated dilation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol 2005; 95:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/68\">",
"      Atmaca Y, Ozdemir AO, Ozdol C, et al. Angiographic evaluation of myocardial perfusion in patients with syndrome X. Am J Cardiol 2005; 96:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/69\">",
"      Leone F, Macchiusi A, Ricci R, et al. Acute myocardial infarction from spontaneous coronary artery dissection a case report and review of the literature. Cardiol Rev 2004; 12:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/70\">",
"      Alfonso F. Spontaneous coronary artery dissection: new insights from the tip of the iceberg? Circulation 2012; 126:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/71\">",
"      Basso C, Morgagni GL, Thiene G. Spontaneous coronary artery dissection: a neglected cause of acute myocardial ischaemia and sudden death. Heart 1996; 75:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/72\">",
"      Tweet MS, Hayes SN, Pitta SR, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation 2012; 126:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/73\">",
"      DeMaio SJ Jr, Kinsella SH, Silverman ME. Clinical course and long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol 1989; 64:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/74\">",
"      Jorgensen MB, Aharonian V, Mansukhani P, Mahrer PR. Spontaneous coronary dissection: a cluster of cases with this rare finding. Am Heart J 1994; 127:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/75\">",
"      Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. Ann Intern Med 1996; 125:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/76\">",
"      Buys EM, Suttorp MJ, Morshuis WJ, Plokker HW. Extension of a spontaneous coronary artery dissection due to thrombolytic therapy. Cathet Cardiovasc Diagn 1994; 33:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41113/abstract/77\">",
"      Zupan I, Noc M, Trinkaus D, Popovic M. Double vessel extension of spontaneous left main coronary artery dissection in young women treated with thrombolytics. Catheter Cardiovasc Interv 2001; 52:226.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1467 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41113=[""].join("\n");
var outline_f40_9_41113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other presentations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC TESTING FOR SUSPECTED CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Noninvasive testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - For episodic chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - After non-ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Gender bias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Non-CHD causes of chest pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cardiac syndrome X or coronary microvascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Stress-induced cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Spontaneous coronary artery dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1467|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/4/18509\" title=\"figure 1\">",
"      Incidence of sudden death in men and women increases with age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/17/32029\" title=\"figure 2\">",
"      Heart failure predicts sudden cardiac death and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1467|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/8/6284\" title=\"table 1A\">",
"      Pretest probability of CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/46/17132\" title=\"table 1B\">",
"      Pretest probability of CHD in CASS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/54/7012?source=related_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14376?source=related_link\">",
"      Radiation dose and risk of malignancy from cardiovascular imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29257?source=related_link\">",
"      Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_9_41114="Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization";
var content_f40_9_41114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Steven A Curley, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Keith E Stuart, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Jonathan M Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Robert L Carithers, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/9/41114/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/9/41114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H361319942\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently occurs in the setting of cirrhosis. The patient's hepatic reserve often dictates therapeutic options (",
"    <a class=\"graphic graphic_table graphicRef69726 \" href=\"mobipreview.htm?7/51/7996\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    ). Treatment options are divided into surgical therapies (ie, resection, and orthotopic liver transplantation [OLT]), and nonsurgical therapies (ie, radiofrequency ablation [RFA] and other thermal methods of tumor ablation, percutaneous ethanol injection [PEI], cryoablation, transarterial chemoembolization [TACE], radiation therapy [RT], radioembolization, and systemic therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361319949\">",
"    <span class=\"h2\">",
"     Treatment algorithms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general approach to the treatment of HCC is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"mobipreview.htm?40/37/41567\">",
"     algorithm 1",
"    </a>",
"    ). An alternative treatment algorithm is used by the Barcelona group (",
"    <a class=\"graphic graphic_algorithm graphicRef69566 \" href=\"mobipreview.htm?11/36/11855\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/2\">",
"     2",
"    </a>",
"    ]. However, attempts to generate algorithmic approaches to the treatment of HCC are difficult since new treatments and indications for various treatments are evolving rapidly. Furthermore, therapeutic approaches tend to vary based upon the available expertise, as well as variability in the criteria for hepatic resection and orthotopic liver transplantation. These issues and a general approach to treatment of HCC are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457341302\">",
"    <span class=\"h2\">",
"     Importance of comprehensive multidisciplinary care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A majority of patients with HCC have underlying liver disease, which may be related to infection with hepatitis B virus (HBV)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatitis C virus (HCV). Furthermore, patients who undergo any of these forms of therapy are at high risk for recurrent disease and of progression to liver failure. It is important that patients with more advanced liver disease have proper monitoring, assessment, and treatment of their underlying liver disease, which may have a major impact on longer term survival. Comprehensive care of patients with cirrhosis includes antiviral therapy for HBV and HCV, immunization against hepatitis A and HBV (if indicated), and endoscopic screening and surveillance for varices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1248650356\">",
"     'Issues related to hepatitis B'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic review will cover transarterial embolization, radiation therapy, and therapeutic radioembolization. Other nonsurgical therapies (RFA, PEI, cryoablation, microwave and laser coagulation) are discussed elsewhere, as are resection, liver transplantation, and systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361320196\">",
"    <span class=\"h1\">",
"     ASSESSING RESPONSE TO LOCOREGIONAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard methods to assess treatment response (eg, unidimensional RECIST criteria (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 3",
"    </a>",
"    ), bidimensional perpendicular measurement using WHO criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/3\">",
"     3",
"    </a>",
"    ]) involve measurement of tumor dimensions before and after treatment. Methods such as these disregard the extent of necrosis, which is the end result of locoregional ablative therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typically the efficacy of percutaneous ablation therapy is assessed by dynamic CT or MRI one month after therapy. Although not entirely reliable, the absence of contrast uptake within the tumor is thought to reflect tumor necrosis, while the persistence of contrast uptake indicates persistent disease. Recurrence of tumor in the treated area (or elsewhere) is signaled by the reappearance of vascular enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the European Association for Study of the Liver (EASL) suggest that estimated reduction in viable tumor burden using dynamic imaging techniques be incorporated into definitions for response in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response (CR) &mdash; Absence of enhanced tumor areas, reflecting complete necrosis",
"     </li>",
"     <li>",
"      Partial response (PR) &mdash; A &gt;50 percent decrease in enhanced areas, reflecting partial tissue necrosis",
"     </li>",
"     <li>",
"      Progressive disease (PD) &mdash; An increase &gt;25 percent in the size of &ge;1 measurable lesion or appearance of a new lesion",
"     </li>",
"     <li>",
"      Stable disease &mdash; Any tumor response between PR and PD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others have proposed a modification in RECIST for HCC for use in formal response assessment, which parallels the definitions of conventional RECIST, and measures the amount of residual viable tumor tissue by summing the length of the remnant viable parts (",
"    <a class=\"graphic graphic_table graphicRef58792 \" href=\"mobipreview.htm?27/46/28396\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little inter-method agreement between \"response rates\" as assessed by EASL and standard",
"    <span class=\"nowrap\">",
"     RECIST/WHO",
"    </span>",
"    criteria. However, extensive necrosis as detected by any method represents a favorable independent prognostic factor for survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the subset of patients with an elevated alpha-fetoprotein (AFP), this marker can be useful to follow response and provide an early screening test for progression by imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Unfortunately, AFP levels are not elevated in up to 40 percent of patients with HCC &lt;2 cm in diameter and in 28 percent of those with tumors between 2 and 5 cm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Alpha-fetoprotein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650293\">",
"    <span class=\"h1\">",
"     TRANSARTERIAL EMBOLIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the blood supply to an HCC is derived from the hepatic artery rather than the portal vein. This has led to the development of techniques designed to eliminate the tumor's blood supply by particle embolization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    directly infuse cytotoxic chemotherapy into the branch of the hepatic artery that feeds the tumor.",
"   </p>",
"   <p>",
"    There is marked variability in the types of procedures that have been used for transarterial therapy: bland particle embolization, transarterial chemoembolization (TACE) without or with lipiodol, and transarterial chemotherapy alone or with lipiodol. Bland particle embolization, which relies solely on induction of tumor ischemia by disruption of the blood supply to the tumor, has been utilized successfully for the treatment of both unresectable and recurrent HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Two meta-analyses have failed to show a significant survival difference between transarterial embolization and transarterial chemoembolization, although there was a trend toward longer survival with TACE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of published experience is with TACE, in which transarterial embolization is combined with the prior injection into the hepatic artery of chemotherapeutic agents, without or with lipiodol (which is sometimes called transarterial oily chemoembolization). This is the procedure that has been shown to improve survival in two randomized trials involving patients with unresectable HCC and as a result, is the most commonly used technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361321044\">",
"    <span class=\"h2\">",
"     Technique for TACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methodology for TACE varies; the term has been used to refer to the injection of a chemotherapeutic agent into the hepatic artery with or without lipiodol, and with or without a procoagulant material. Lipiodol is an oily contrast agent that is thought to promote intratumoral chemotherapy retention; however, it probably does not contribute to arterial occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. While it is thought that chemolipiodolization and embolization have synergistic antitumor activities (the former by inducing high intratumoral concentrations of cytotoxic drugs, and the latter, by cutting off the blood supply to the tumor), this has never been proven.",
"   </p>",
"   <p>",
"    Few randomized trials have compared the different techniques for TACE. In theory, embolization should enhance the effect of chemotherapy by causing metabolically active cell membrane pumps to fail, thereby overcoming drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/20\">",
"     20",
"    </a>",
"    ]. However, whether simultaneous or sequential occlusion of the hepatic artery until there is stagnation of blood flow to the tumor results in greater antitumor efficacy than chemotherapy alone has not been proven. Furthermore, neither the optimal chemotherapeutic agent nor the best embolization method (ie, gelatin sponge [Gelfoam], degradable starch microspheres, polyvinyl alcohol) has been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of transarterial therapy techniques came to the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In comparing conventional TACE versus bland embolization alone (three randomized trials, 412 patients), survival was no better with the addition of chemotherapy.",
"     </li>",
"     <li>",
"      There was no evidence of benefit from the addition of lipiodol to TACE.",
"     </li>",
"     <li>",
"      Although gelatin sponge was the most frequently used embolic agent and there were no randomized trials directly comparing both approaches, the authors of this review concluded that polyvinyl alcohol (PVA) might be superior to other forms of embolization. PVA causes permanent or semipermanent arterial occlusion, while gelatin occludes the artery only temporarily with recanalization taking place within two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/22\">",
"       22",
"      </a>",
"      ]. Furthermore, in a comparative nonrandomized study, similar survival was seen after the use of PVA compared to the use of gelatin sponge, and fewer sessions were required (mean 2.2 versus 1.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, the benefit of embolization as a component of TACE was called into question by a later trial in which 243 patients were randomly assigned to chemolipiodolization using three chemotherapeutic agents with or without subsequent sponge embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/24\">",
"     24",
"    </a>",
"    ]. Outcomes were not significant better in the group that received sponge embolization (median overall survival 10.5 versus 10.1 months, median progression-free survival 3.6 versus 3.1 months).",
"   </p>",
"   <p>",
"    Nevertheless, despite these results, intraarterial injection of chemotherapy with lipiodol, followed by injection of a procoagulant material, continues to be the most commonly used approach to hepatic arterial embolization.",
"   </p>",
"   <p>",
"    The TACE procedure starts with catheterization of the hepatic artery followed by identification of the tumor&rsquo;s feeding vessel. The selectivity of catheter placement determines the amount of liver embolized. For patients with solitary tumors, the catheter can be placed into a second-order (selective) or third-order (superselective) branch off the right or left hepatic artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/25\">",
"     25",
"    </a>",
"    ]. In cases where there are multiple tumors in one lobe, a lobar chemoembolization may be needed. If there is disease involving both lobes, bilateral TACE must be performed sequentially. Whole liver chemoembolization must be avoided because of the potential for serious liver injury.",
"   </p>",
"   <p>",
"    Once the feeding vessel is selected, the chemotherapy is then infused.",
"   </p>",
"   <p>",
"    The choice of chemotherapeutic agent is not standardized, and a variety of agents have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/22,26-31\">",
"     22,26-31",
"    </a>",
"    ]. We use single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    60 mg plus lipiodol (20 mL), emulsified with water-soluble contrast (10 mL). Others recommend a mixture of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (50 to 100 mg), doxorubicin (20 to 50 mg), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C (10 mg), mixed in 10 mL of water soluble contrast and then emulsified in an equivalent volume of lipiodol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. The superiority of a three-drug cocktail for chemolipiodolization using a platinum agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and mitomycin as compared to epirubicin alone was suggested in a single-blind phase III trial comparing both approaches in 243 patients; both groups received starch embolization after the chemolipiodolization procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/24\">",
"     24",
"    </a>",
"    ]. A third arm included three-drug chemolipiodolization followed by no starch embolization, the comparison of this arm versus the group receiving three-drug chemolipiodolization followed by starch embolization is described above.",
"   </p>",
"   <p>",
"    Among the patients randomly assigned to three-drug versus single-drug chemolipiodolization, the three drug cocktail was associated with significantly higher objective response rates (46 versus 19 percent) and better median overall survival (median 10.5 versus 5.9 months), but no significant difference in median progression-free survival (3.6 versus 3.1 months). However, one potential reason for the difference in survival outcomes could be differences in subsequent post-TACE treatments, all of which were more commonly administered to patients who received the three-drug cocktail (ie, subsequent hepatic resection in 15 versus 9, RFA in 32 versus 6, and TACE in 33 versus 15). These data raise the possibility that differences in underlying liver function, a major prognostic factor, and not the specific chemotherapy drug cocktail, might have been responsible for at least some of the differences in median overall survival. Although nearly twice as many patients receiving the three-drug cocktail had adverse events of grade 3 or higher (22 versus 12, and mainly accounted for by hematologic toxicity), the difference between the groups was not statistically significant. As such, in our view, the results of this study should not change current practice. &nbsp;",
"   </p>",
"   <p>",
"    In the event that powdered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    is not available, equivalent doses of the premixed solution should be used and an attempt made to minimize overall volume. Regardless of the specific chemotherapy \"cocktail\" used, the resulting emulsion must be constantly shaken during the infusion, which is then followed by 0.1 to 0.2 mL of 150 to 250 micron PVA dry particles or gelatin sponge pledgets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We administer broad spectrum IV antibiotics and antiemetics (a serotonin receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) just prior to the procedure. Following TACE, patients are hospitalized until oral intake is adequate and pain is well controlled. In our experience, most patients are discharged within 48 hours of the procedure. However, in the meta-analysis cited above, the median postprocedure stay was five days, which depended on the duration of postembolization syndrome or the appearance of more severe complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important components of postprocedure care include aggressive hydration (3L per 24 hours), continued antibiotics (parenteral for 24 hours), prophylaxis against nausea and vomiting (typically",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , with a serotonin receptor antagonist and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    only as needed), adequate narcotic analgesia (parenteral or oral as needed), and monitoring of electrolytes and liver function tests. Whether prophylactic antibiotics are needed after discharge is controversial. Some recommend five days of oral broad spectrum coverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/25\">",
"     25",
"    </a>",
"    ] while others conclude that prophylactic antibiotics are not routinely necessary but recommended in patients with biliary reconstruction and impaired liver function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/34\">",
"     34",
"    </a>",
"    ]. We typically administer five days of an oral broad spectrum antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) after discharge. (See",
"    <a class=\"local\" href=\"#H1248650342\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650307\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to TACE include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thrombus in the main portal vein and portal vein obstruction",
"     </li>",
"     <li>",
"      Encephalopathy",
"     </li>",
"     <li>",
"      Biliary obstruction",
"     </li>",
"     <li>",
"      Child-Pugh C cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a main portal vein thrombus and portal vein obstruction are poor candidates for TACE. They are at higher risk for ischemic necrosis of viable liver, liver failure, and death, as are patients with advanced liver disease. Furthermore, patients with macroscopic vascular invasion have a very poor prognosis, no matter what treatment they receive. (See",
"    <a class=\"local\" href=\"#H7665170\">",
"     'Selecting candidates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Relative contraindications include a variety of other factors including, but not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum bilirubin &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Lactate dehydrogenase &gt;425",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"     </li>",
"     <li>",
"      Aspartate aminotransferase &gt;100",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"     </li>",
"     <li>",
"      Tumor burden involving &gt;50 percent of the liver",
"     </li>",
"     <li>",
"      Cardiac or renal insufficiency",
"     </li>",
"     <li>",
"      Ascites, recent variceal bleed, or significant thrombocytopenia",
"     </li>",
"     <li>",
"      Transjugular intrahepatic portosystemic shunt (TIPS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650314\">",
"    <span class=\"h2\">",
"     Indications and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;TACE has been used in three settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of large unresectable HCC not suitable for local ablation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link\">",
"       \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior to resection",
"     </li>",
"     <li>",
"      In patients awaiting orthotopic liver transplantation to reduce the rate of dropout because of tumor progression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefit in any of these settings is highly dependent upon case mix, including tumor-related factors and the severity of preexisting liver dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650321\">",
"    <span class=\"h3\">",
"     Primary treatment of large unresectable HCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;TACE is typically used in patients who have large (ie, &gt;10 cm) or multifocal HCCs that are not amenable to other local treatments. Approximately 35 to 40 percent of patients have an objective antitumor response (&ge;25 percent reduction in tumor size) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/11,36-39\">",
"     11,36-39",
"    </a>",
"    ]. However, many tumors do not decrease in size even after successful treatment, forcing the use of surrogate markers of response (lack of contrast enhancement on CT or MRI, lipiodol deposition in targeted tumors, decline in AFP) to determine the presence of tumor necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/5,6,13\">",
"     5,6,13",
"    </a>",
"    ]. When criteria are used that take into account the area of intratumoral necrosis to estimate the reduction in tumor burden, rate of objective response ranges from 16 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/7,40\">",
"     7,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H361320196\">",
"     'Assessing response to locoregional therapies'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    Despite the widespread acceptance of TACE in patients with advanced HCC and the suggestion of prolonged survival in multiple phase II studies, three of five large randomized trials failed to show a survival advantage for TACE compared to a variety of other treatments or conservative management in patients with advanced unresectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/38,39,41\">",
"     38,39,41",
"    </a>",
"    ]. Comparison of these studies is difficult due to differences in embolization techniques, patient selection, and the variable number of repeated treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, two controlled trials have shown a survival advantage for TACE compared to symptomatic treatment alone in selected patients with unresectable HCC and preserved liver function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/11,42\">",
"     11,42",
"    </a>",
"    ]. Three meta-analyses have been conducted, two of which lend further support for a survival benefit of arterial embolization in patients with unresectable HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18,40\">",
"     18,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, compared to control (either conservative management or suboptimal therapy [eg, intravenous 5-fluorouracil]), there was a statistically significant improvement in two-year survival with arterial embolization (OR 0.53, 95% CI 0.32-0.89) that was evident for chemoembolization (TACE) but not bland particle embolization alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second meta-analysis also showed a significant survival benefit for TACE relative to no or suboptimal treatment (OR 0.705, 95% CI 0.50-0.99), but was unable to show a survival advantage for TACE over bland arterial embolization alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more recent (2012) Cochrane meta-analysis of nine randomized trials failed to find evidence of a survival benefit from either TACE or bland embolization (HR for death 0.81, 95% CI 0.64-1.02); however, the analysis included four trials of preoperative or postoperative TACE or bland embolization in patients undergoing resection of localized HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/43\">",
"     43",
"    </a>",
"    ]. In a separate analysis of three trials of TACE in patients with advanced HCC (including both of the positive trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/11,41,42\">",
"     11,41,42",
"    </a>",
"    ], there was still no evidence of a statistically significant survival benefit (HR for death 0.65, 95% CI 0.40-1.05). &nbsp;",
"   </p>",
"   <p>",
"    One potential reason for these disparate results may be selection bias. The importance of considering patient selection when interpreting the results of these studies cannot be overemphasized. As an example, in one of the randomized trials comparing TACE versus symptomatic treatment alone, TACE significantly prolonged one-year survival (82 versus 63 percent), but survival in the control group was markedly higher than that reported in most treatment studies for advanced HCC (median survival usually less than six months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H3#H3\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Estimating life expectancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, the degree to which TACE prolongs survival in patients with unresectable HCC remains an area of uncertainty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7665170\">",
"    <span class=\"h4\">",
"     Selecting candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best candidates for TACE are patients with unresectable lesions without vascular invasion or extrahepatic spread, and preserved liver function (ie, Child-Pugh A or B cirrhosis, (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    )). Baseline liver function, as assessed by Child-Pugh classification (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    ), or the CLIP score (",
"    <a class=\"graphic graphic_table graphicRef69726 \" href=\"mobipreview.htm?7/51/7996\">",
"     table 1",
"    </a>",
"    ), seems to be the most accurate factor predicting survival in patients with unresectable HCC treated with TACE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While patients with portal vein thrombus have been excluded from TACE in the past, there is now some evidence that patients who have thrombus not involving the main portal vein may tolerate the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/44,47,48\">",
"     44,47,48",
"    </a>",
"    ]. In a study of TACE in 32 patients with portal vein thrombus, there were no deaths within 30 days after the procedure, and there were no cases of acute liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/44\">",
"     44",
"    </a>",
"    ]. Median survival was 9.5 months. (See",
"    <a class=\"local\" href=\"#H1248650307\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Complete portal vein occlusion is associated with a worse outcome than partial or segmental occlusion, and the choice of using TACE (or other embolic therapies such as radioembolization) in these patients should take into consideration both the size and location of the tumor. As an example, if there is a 4 cm lesion that is inaccessible otherwise, distal to the takeoff of the right hepatic artery, that can be treated super selectively so as not to embolize much of the right lobe that is affected by a right portal vein thrombosis, then treatment with TACE is probably safe.",
"   </p>",
"   <p>",
"    The relatively large subgroup of patients with major portal vein thrombus are also candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and there is no evidence that locoregional therapies benefit these patients above and beyond what might be accomplished with sorafenib. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, fewer than 2 percent of patients achieve a complete response from a single round of treatment with TACE. During follow-up, residual tumor nests recover their blood supply and begin to regrow. This has prompted many centers to repeat the TACE procedure at regular intervals in an attempt to maximize benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the decision to retreat must be based upon assessment of tumor response and hepatic reserve. TACE should be limited to the minimum number of procedures necessary to control the tumor. The benefit of multiple repeated cycles of TACE must be weighed against the adverse effects of the procedure, particularly in those with cirrhosis and poor hepatic reserve.",
"   </p>",
"   <p>",
"    TACE causes some degree of ischemic hepatic damage, which has the potential to lead to hepatic decompensation. (See",
"    <a class=\"local\" href=\"#H361320196\">",
"     'Assessing response to locoregional therapies'",
"    </a>",
"    above.) Multiple courses of TACE, especially if spaced too closely together, can increase deaths from liver failure despite successful tumor shrinkage, and these excess deaths from deterioration of liver function may counterbalance any prolongation of survival that results from enhanced tumor control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/49\">",
"     49",
"    </a>",
"    ]. TACE may cause hepatic artery damage, the likelihood of which is higher in patients with impaired liver function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The clinical relevance of this complication is unclear, although it has the potential to limit the ability to perform repeated procedures. Hepatic artery interruption by repeated TACE or arterial dissection also leads to the development of extrahepatic collateralization, which may create an alternative blood supply to the tumor, and contribute to treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For all of these reasons, we do not generally repeat the TACE procedure unless there is clear evidence of progressive tumor growth in the treated areas. In general, if both the right and left lobes require treatment, we wait one month in between procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43986409\">",
"    <span class=\"h4\">",
"     TACE plus sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    is a multikinase inhibitor acting on the vascular endothelial growth factor receptor (VEGFR), among others. Findings from the European SHARP trial, which showed that sorafenib significantly prolonged survival over supportive care alone in patients with advanced HCC, established sorafenib monotherapy as a new reference standard for systemic treatment of advanced HCC and formed the basis for approval of sorafenib for unresectable HCC in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been hypothesized that administration",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    might be useful to target upregulation of TACE-induced angiogenic factors, and therefore, improve outcomes from TACE treatment; uncontrolled studies are promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], but the only way to prove benefit over TACE alone is with a randomized trial .",
"   </p>",
"   <p>",
"    The benefit of combined therapy over TACE alone was directly addressed in two randomized phase II trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial 80 patients with HCV-related HCC and Child-Pugh class A cirrhosis who had a clinical complete response to TACE (as assessed by contrast-enhanced CT scan 30 days post-TACE) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (400 mg twice daily) or placebo, both given until tumor progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/55\">",
"       55",
"      </a>",
"      ]. TACE was repeated at intervals of four to six weeks (maximum of four) until complete tumor necrosis was detected. A similar number of patients in both the sorafenib and placebo groups required more than one TACE procedure to achieve a complete response. A similar number of patients in both groups withdrew during the study (9 of 40 in each), but in the sorafenib group, this was almost entirely due to grade 3 or 4 toxicity (which included hand foot skin reaction, bone marrow suppression, and uncontrolled diarrhea).",
"      <br/>",
"      <br/>",
"      Median time to tumor progression (the primary endpoint) was longer in the sorafenib group (9.2 versus 4.9 months). A p value of 0.001 was reported, but the statistical methodology was unclear. The sorafenib group also had fewer intrahepatic tumor recurrences within six months of TACE (22 versus 71), but over time, the proportion of patients with local progression was not significantly different (45 versus 52 percent). Overall survival was not reported.",
"     </li>",
"     <li>",
"      The second trial, which has only been reported in abstract form (the SPACE trial), randomly assigned 307 patients to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      or placebo; all patients underwent TACE with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      eluting beads three to seven days after the first dose of study drug, which was repeated on day 1 of months 3, 7, and 13, and every six months thereafter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/56\">",
"       56",
"      </a>",
"      ]. In a preliminary report at the 2012 ASCO Gastrointestinal Cancer symposium, there were modest trends toward better TTP (hazard ratio [HR] 0.797, 95% CI 0.588-1.080) and overall survival (HR 0.898, 95% CI 0.606-1.330) with combined therapy but neither difference was statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these results suggest that at best, the concomitant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    might modestly delay but not prevent tumor progression after TACE. Larger, well-designed phase III trials with a survival endpoint are needed before it can be concluded that there is any benefit for the addition of sorafenib after TACE. Such a trial, the TACE2 trial, is underway comparing TACE with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    eluting beads with or without sorafenib in patients with unresectable HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/57\">",
"     57",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650328\">",
"    <span class=\"h3\">",
"     Prior to resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of uncontrolled series and at least one controlled trial suggest that TACE used prior to an attempt at resection is associated with",
"    <strong>",
"     increased",
"    </strong>",
"    mortality. Thus, TACE is not indicated prior to resection. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link&amp;anchor=H969401877#H969401877\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\", section on 'Neoadjuvant therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650335\">",
"    <span class=\"h3\">",
"     Prior to liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the granting of MELD exception points for liver transplant candidates with HCC whose tumors are within the Milan criteria, most potential recipients wait at least six months to a year for a donor organ (unless they are candidates for living donor transplantation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H21#H21\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Living donor transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several small series have demonstrated the feasibility of TACE prior to orthotopic liver transplantation in patients who are estimated to have a long wait time to transplant. Despite its uncertain benefit, it remains a common method in many transplant centers to limit the amount of viable tumor at the time of transplantation, to help bridge the often prolonged waiting period while a patient is listed and awaiting a donor organ, and to improve selection for transplantation based on tumor biology. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H11#H11\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Chemoembolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650342\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effect of TACE, which occurs in 60 to 80 percent of patients, is postembolization syndrome. This consists of varying degrees of right upper quadrant pain, nausea, a moderate degree of ileus, fatigue, fever, and transient elevation of AST, ALT and bilirubin values. Symptoms are usually self-limited, lasting three to four days; full recovery is typical within 7 to 10 days.",
"   </p>",
"   <p>",
"    Some suggest that tumor necrosis is the main cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/38,58\">",
"     38,58",
"    </a>",
"    ], while more recent reports attribute the postembolization syndrome to ischemic damage to normal liver parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Prospective studies are needed to definitively answer the question of whether postembolization syndrome is a side effect to be avoided or an index of the efficacy of the procedure.",
"   </p>",
"   <p>",
"    Although most of the chemotherapy is retained in the liver, there is some systemic exposure, and patients are at risk for nausea, vomiting, bone marrow depression. The use of drug-eluting beads reduces systemic exposure to the chemotherapy. (See",
"    <a class=\"local\" href=\"#H1248650349\">",
"     'Drug-eluting beads'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Serious complications of TACE include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment-induced ischemic damage to the nontumor-bearing liver is thought responsible for precipitating or exacerbating liver failure. In the meta-analysis cited above, liver failure rates averaged 7.5 percent, but the wide range (0 to 49 percent) likely reflects the heterogeneous patient population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The incidence of hepatic decompensation following TACE is closely related to pretreatment hepatic function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/36,61\">",
"       36,61",
"      </a>",
"      ]. In a prospective study of 197 sessions of TACE performed in 59 patients with HCC, acute hepatic decompensation developed after 39 sessions (20 percent), and was irreversible in six (3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/36\">",
"       36",
"      </a>",
"      ]. Patients with irreversible changes were significantly more likely to have higher pre-TACE bilirubin levels, more prolonged prothrombin time, and more advanced cirrhosis.",
"     </li>",
"     <li>",
"      Other less common ischemic complications include hepatic abscess (2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/62\">",
"       62",
"      </a>",
"      ]), acute cholecystitis, and injury to the biliary tract. Bile duct injury (subcapsular bilomas, focal stricture of the hepatic or common bile duct, diffuse dilation of the intrahepatic bile ducts) is reported in 0.5 to 2 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18,63\">",
"       18,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastroduodenal ulceration is a recognized complication of TACE (3 to 5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18,64\">",
"       18,64",
"      </a>",
"      ]. Among the possible explanations are regurgitation of embolizing particles into the right or left gastric artery, the presence of anatomic variants (eg, right gastric artery too distal to the proper hepatic artery or accessory left gastric artery arising from the left hepatic artery) or stress ulcers.",
"     </li>",
"     <li>",
"      Renal dysfunction (2 percent) is also reported.",
"     </li>",
"     <li>",
"      Pulmonary and cerebral lipiodol embolization are rare, but potentially fatal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/65-67\">",
"       65-67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interstitial pneumonia is also described in which radiographic studies are not suggestive of lipiodol retention in the lung [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/68\">",
"       68",
"      </a>",
"      ]. Histologic evaluation (and the fact that most cases occurred after a second injection) raised the possibility of an immunoallergic reaction, with a possible contribution from radiation pneumonitis. However, hypereosinophilia was absent and glucocorticoid therapy seemed to be of little value. Of note, 12 of the 15 patients reported in this series died, mostly of acute respiratory failure.",
"     </li>",
"     <li>",
"      Treatment-related mortality rates from TACE are approximately 2 to 3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18,32\">",
"       18,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650349\">",
"    <span class=\"h2\">",
"     Drug-eluting beads",
"    </span>",
"    &nbsp;&mdash;&nbsp;A newer approach to TACE uses drug-eluting beads (DEBs) that slowly release chemotherapy, thus diminishing systemic toxicity. Early results from retrospective reports and several small prospective randomized trials suggest similar rates of tumor control as with conventional TACE, with lower rates of serious hepatobiliary toxicity, although follow-up is short in most series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/69-76\">",
"     69-76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of seven studies comparing conventional TACE versus DEB-TACE (five prospective randomized trials and two retrospective comparative reports, totaling 693 patients) concluded that the pooled estimates for tumor response with DEB-TACE were not significantly different from those of conventional TACE (odds ratio [OR] for disease control 1.37, 95% CI 0.95-1.98) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparative toxicity was addressed in the largest randomized trial, the PRECISION V trial, in which conventional TACE using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (50 to 75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      was directly compared to DEB-TACE (150 mg doxorubicin per procedure) in 212 patients with Child-Pugh",
"      <span class=\"nowrap\">",
"       A/B",
"      </span>",
"      cirrhosis and unresectable HCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/70\">",
"       70",
"      </a>",
"      ]. The DEB group had lower rates of treatment-emergent adverse events in the hepatobiliary system (16 versus 25 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/71\">",
"       71",
"      </a>",
"      ]. The mean maximum postchemoembolization alanine transaminase increase with DEB-TACE was 50 percent less than in the conventional TACE group (p&lt;0.001), and the mean maximum aspartate transaminase increase was 41 percent lower. Furthermore, despite a higher mean total dose of doxorubicin in the DEB-TACE group (295 versus 233 mg), there was a small but statistically significant difference in mean change from baseline in left ventricular ejection fraction (LVEF) of 4 percentage points that favored DEB-TACE group. The incidence of postembolization syndrome was similar between both groups (25 versus 26 percent for DEB-TACE and conventional TACE). On the other hand, treatment-emergent gastrointestinal adverse events occurred more often in patients treated with DEB-TACE (61 versus 45 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     Doxorubicin",
"    </a>",
"    -eluting beads are approved in Europe and Canada (DC Bead, Biocompatibles International Inc). In the US, LC beads (Angiodynamics, Inc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/77\">",
"     77",
"    </a>",
"    ]) are commercially available in a variety of sizes and approved as a medical device.",
"   </p>",
"   <p>",
"    Irinotecan-eluting beads are beginning to be studied, but only limited data are available, particularly regarding toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650356\">",
"    <span class=\"h2\">",
"     Issues related to hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;TACE is a risk factor for reactivation of hepatitis B virus infection (HBV), and antiviral prophylaxis is recommended for patients who are HBsAg positive.&nbsp;At least some data suggest better outcomes among patients undergoing TACE for HBV-associated HCC who are treated concomitantly with nucleoside analogs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Issues related to screening and prophylaxis are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be tested'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650363\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial embolization is a reasonable option for patients with an unresectable HCC that is either too large or multifocal for percutaneous ablation techniques such as RFA, with relatively preserved liver function (Child-Pugh",
"    <span class=\"nowrap\">",
"     A/B,",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    )), and no extrahepatic tumor spread, vascular invasion, or main portal vein thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. Although the evidence is weak, TACE rather than bland embolization alone is recommended in guidelines from the American Association for the Study of Liver Disease (AASLD), and from an expert consensus group of the American Hepato-Pancreato-Biliary Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    recommend chemoembolization, bland embolization, or radioembolization in this setting.",
"   </p>",
"   <p>",
"    We use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    as a single agent at a fixed dose for the procedure, although other centers add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ; there is no evidence that either approach is better. Where available, DEBs may be preferred, although long-term outcomes using this technique are not available.",
"   </p>",
"   <p>",
"    Patient selection is critical to the success and safety of TACE. The best candidates for TACE are patients with unresectable lesions without vascular invasion or extrahepatic spread, and preserved liver function (ie, Child-Pugh A or B cirrhosis, (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    We do not routinely recommend TACE prior to a planned HCC resection. While it is commonly used as a bridging maneuver in patients awaiting liver transplantation, data proving benefit in this setting are lacking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H11#H11\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Chemoembolization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link&amp;anchor=H969401877#H969401877\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\", section on 'Neoadjuvant therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650370\">",
"    <span class=\"h1\">",
"     RADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCC is a radiosensitive tumor, but it is located in an extremely radiosensitive organ. The major drawbacks with RT are the poor radiation tolerance of normal liver and difficulty with tumor localization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650377\">",
"    <span class=\"h2\">",
"     External beam RT with and without TACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited experience with external beam photon irradiation for unresectable HCC suggests that limited fields are tolerable and induce a substantial tumor response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. The largest report included 158 patients who received external beam RT (mean tumor dose 48.2 Gy in daily 1.8 Gy fractions) combined with TACE (n = 107) or after failure of TACE (n = 51) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/87\">",
"     87",
"    </a>",
"    ]. An objective response was seen in 16 (67 percent), one of which was complete. The two-year overall survival rate was 31 percent. Treatment was tolerated without major complications; toxicity included transient abnormal liver function tests (38 percent), fever (20 percent), thrombocytopenia (11 percent), gastroduodenal ulcer (6 percent), and gastroenteritis (5 percent).",
"   </p>",
"   <p>",
"    With the development of three dimensional conformal radiation (3D-CRT) techniques, RT can be more safely delivered to the tumor-bearing parts of the liver with less liver toxicity. Most of the available data are retrospective or single center studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/90-94\">",
"     90-94",
"    </a>",
"    ]. A single French multicenter phase II trial reported sustained local tumor control in 78 percent of patients with early HCC (one nodule &le;5 cm, or two nodules &le;3 cm) who were treated with 3D-CRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the problems with RT is the high intrahepatic recurrence rate, which may be in part attributable to difficulties with target delineation during conventional RT treatment planning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/96\">",
"     96",
"    </a>",
"    ]. This provides the rationale for combining external beam RT with TACE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/94,97-102\">",
"     94,97-102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective trial, 40 patients with unresectable HCC received 3D-CRT after an incomplete response to one or two courses of TACE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/94\">",
"       94",
"      </a>",
"      ]. The objective response rate was 63 percent, the complete response rate was 21 percent, and survival at one and two years was 72 and 46 percent. Only nine patients had disease progression within the irradiated field during follow-up.",
"     </li>",
"     <li>",
"      Combined therapy may be beneficial for patients with portal vein thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/93,103-106\">",
"       93,103-106",
"      </a>",
"      ]. In a registry database series of 412 patients with unresectable HCC complicated by thrombus in the portal vein (49 percent bilateral or main portal vein) who received focal 3D-CRT combined with TACE before or after RT (lipiodol,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      gelatin sponge), 40 percent had an objective response in the portal vein tumor thrombus and 43 percent were still alive at one year; however, grade 3 or 4 hepatotoxicity was seen in 10 percent of patients during or within three months of completion of RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these results are better than can be achieved using 3D-CRT alone or stereotactic hypofractionated RT remain to be seen. Objective response rates to 3D-CRT alone directed to a portal vein thrombus range from 25 to 58 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/92,103,107-110\">",
"     92,103,107-110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650405\">",
"    <span class=\"h2\">",
"     IMRT and stereotactic body radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technologic developments in delivering more precisely targeted RT (intensity-modulated RT, [IMRT] [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/111\">",
"     111",
"    </a>",
"    ] and image-guided approaches, including stereotactic body radiotherapy [SBRT]) may improve the",
"    <span class=\"nowrap\">",
"     benefit/toxicity",
"    </span>",
"    of radiation therapy, although they will not alter the high recurrence rates in other nontreated areas of the liver.",
"   </p>",
"   <p>",
"    SBRT is a technique in which a single (sometimes called stereotactic radiosurgery) or limited number of high dose RT fractions are delivered to a small, precisely-defined target by using multiple, nonparallel radiation beams. The beams converge on the target lesion, minimizing radiation exposure to adjacent normal tissue. This targeting allows treatment in either a single or limited number of dose fractions.",
"   </p>",
"   <p>",
"    Stereotactic approaches to RT are increasingly being used for metastatic liver tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link&amp;anchor=H6#H6\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Liver metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with SBRT for primary liver tumors is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/105,112-118\">",
"     105,112-118",
"    </a>",
"    ]. In the largest series, 42 patients with unresectable HCC (38 Child-Pugh A, the rest B) and a HCC with tumor volume &le;100 cc who were not eligible for local ablation or surgical resection were treated with SBRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/118\">",
"     118",
"    </a>",
"    ]. The in-field complete response rate was 60 percent, and the in-field progression-free survival at three years was 68 percent. Out of field hepatic progression occurred in 18 (43 percent) and distant metastases in 12 (29 percent). The overall response rate at three years was 59 percent. Toxicity included grade 2 liver enzyme elevation (8 percent), elevated bilirubin (1 percent), grade 2 leucopenia (3 percent) and one late liver failure.",
"   </p>",
"   <p>",
"    This approach seems most applicable to patients with relatively small HCCs who are either inoperable or who refuse operation. Whether SBRT is a more effective or less toxic approach than RFA in these patients will require a randomized trial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Radiofrequency ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650412\">",
"    <span class=\"h2\">",
"     Charged particle RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing body of evidence, primarily from Japan, supporting the use of proton beam irradiation, particularly for patients with large tumors or portal vein thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/119-125\">",
"     119-125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 162 patients with 192 HCCs were treated with proton beam irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/119\">",
"       119",
"      </a>",
"      ]. Most tumors had a diameter of 3 to 5 cm. The majority of the patients had received some form of previous, nonsurgical therapy. The five-year local control rate was 87 percent. Overall survival at five years was 24 percent, with most patients dying from metachronous intrahepatic lesions. Acute and late gastrointestinal toxicities were uncommon.",
"     </li>",
"     <li>",
"      The utility of proton beam therapy in the setting of portal vein thrombus was shown in a report of 12 patients who had HCC and tumor thrombus in the main trunk or major branches of the portal vein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/122\">",
"       122",
"      </a>",
"      ]. The objective response rate was 100 percent, a far higher value than reported in previous studies of patients with portal vein thrombus, and five recanalized their portal vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An unresolved issue is whether these outcomes could be achieved with modern 3D-CRT and which patients, if any, would do better with proton beam therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/126\">",
"     126",
"    </a>",
"    ]. Proton beam irradiation is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522744318\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT using modern treatment techniques such as 3D-CRT induces sustained tumor responses with an acceptable safety profile. However, there are no studies demonstrating an impact on survival and no consensus as to the optimal use of this therapy, with or without TACE. 3D-CRT may be a reasonable option in patients who have failed other local modalities, have no extrahepatic disease, limited tumor burden, and relatively good liver function.",
"   </p>",
"   <p>",
"    SBRT seems most applicable to patients with relatively small HCCs who are either inoperable or who refuse operation. Whether SBRT is a more effective or less toxic approach than RFA in these patients is unclear. Where available, proton beam irradiation may be a reasonable approach for patients with a large HCC and associated portal vein thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1248650419\">",
"    <span class=\"h2\">",
"     Radioembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, external beam RT for treatment of intrahepatic malignancies is limited by low tolerance of normal tissues. An alternative means of delivering focal RT employs radioactive isotopes (eg, iodine-131 [131-I]-labeled lipiodol or yttrium-90 [90-Y]-tagged glass or resin microspheres) that are delivered selectively to the tumor via the hepatic artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441997251\">",
"    <span class=\"h3\">",
"     Iodine 131- labeled lipiodol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data have suggested a survival benefit for use of adjuvant 131-I lipiodol following resection of HCC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link&amp;anchor=H969401884#H969401884\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\", section on 'Postoperative therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few reports have studied 131-I lipiodol in locally unresectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/128-130\">",
"     128-130",
"    </a>",
"    ]. A single trial randomly assigned 142 patients with unresectable HCC to 131-I labeled lipiodol versus TACE using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/129\">",
"     129",
"    </a>",
"    ]. Both treatments were repeated at 2, 5, 8, 12, and 18 months. Reduction in tumor size was similar for both treatments (complete or partial response in 16 patients in each group (23 percent)), as were overall survival rates at one and three years (38 and 14 percent for 131-I lipiodol versus 42 and 3 percent for TACE). However, tolerance was much better with 131-I lipiodol (3 versus 29 severe side effects).",
"   </p>",
"   <p>",
"    The use of this agent for locoregional treatment of unresectable HCC, or in the adjuvant setting following resection of an HCC, is limited by lack of availability, at least in the US. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=see_link&amp;anchor=H969401884#H969401884\">",
"     \"Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance\", section on 'Postoperative therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441997270\">",
"    <span class=\"h3\">",
"     Yttrium-90 labeled microspheres",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441999107\">",
"    <span class=\"h4\">",
"     Large unresectable primary HCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioembolization using 90-Y-tagged glass (TheraSphere) or resin (SIR-Spheres) microspheres is safe and probably effective in patients with unresectable HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/131-138\">",
"     131-138",
"    </a>",
"    ]. Both products are commercially available in North America, while the resin product is available worldwide. In the US, 90-Y glass microspheres are approved for treatment of unresectable HCC, under the provisions of a humanitarian device exemption. One of the conditions for approval is that there be Institutional Review Board review and approval before a humanitarian-use device can be used at a facility, as well as continuing review of its use.",
"   </p>",
"   <p>",
"    The long-term efficacy of this approach is best demonstrated by a comprehensive analysis of 291 patients treated with TheraSpheres [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/138\">",
"     138",
"    </a>",
"    ]. The WHO response rate (objective bidimensional measurement of perpendicular tumor size) was 42 percent; by EASL criteria (measuring area of enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/7\">",
"     7",
"    </a>",
"    ]), 57 percent of patients responded (23 percent complete). (See",
"    <a class=\"local\" href=\"#H361320196\">",
"     'Assessing response to locoregional therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At a median follow-up of 31 months, the median time to progression (TTP) was 7.9 months. For patients with Child-Pugh A and B disease (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    ) without portal vein thrombus, it was 15.5 and 13 months, respectively, while for those with Child-Pugh A and B disease with portal vein thrombus it was 5.6 and 5.9 months, respectively. Median survival time was longer for Child-Pugh A rather than B disease (17.2 versus 7.7 months) and for those patients without portal vein thrombosis. Median survival was poor for those patients with Child-Pugh B disease and portal vein thrombosis (2.6 months). The main clinical toxicities were nausea, abdominal pain, fatigue, and transient hyperbilirubinemia; safety results were not reported separately for those patients with and without portal vein thrombosis.",
"   </p>",
"   <p>",
"    Whether these results are better than can be achieved with TACE is unclear; although retrospective analyses suggest similar efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/139\">",
"     139",
"    </a>",
"    ], there are no randomized trials comparing both procedures. One clinical scenario in which radioembolization might be selected over TACE is in patients with a",
"    <span class=\"nowrap\">",
"     branch/lobar",
"    </span>",
"    portal vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/140-143\">",
"     140-143",
"    </a>",
"    ]. On the other hand, as with TACE, thrombosis of the main portal vein is a contraindication to radioembolization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178682735\">",
"    <span class=\"h4\">",
"     Use in patients being considered for liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are less data than with TACE, radioembolization limits disease progression, which may allow patients more time to wait for a donor organ. In addition, patients who are beyond the usual transplantation criteria who do not have malignant portal vein thrombus or extrahepatic disease involvement may be candidates for radioembolization to downstage the disease to within transplant criteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H459410019#H459410019\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Radioembolization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link&amp;anchor=H24#H24\">",
"     \"Liver transplantation for hepatocellular carcinoma\", section on 'Downstaging through neoadjuvant locoregional therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441997277\">",
"    <span class=\"h4\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications occurring after radioembolization include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mild postembolization syndrome with fatigue, constitutional symptoms and abdominal pain (incidence 20 to 55 percent)",
"     </li>",
"     <li>",
"      Hepatic dysfunction, which may be manifest as liver failure (attributed to hepatic sinusoidal injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/147\">",
"       147",
"      </a>",
"      ]) or radioembolization-induced liver disease (RILD, defined as jaundice and ascites appearing one to two months after radioembolization in the absence of tumor progression or bile duct occlusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/147-150\">",
"       147-150",
"      </a>",
"      ]).",
"      <br/>",
"      <br/>",
"      There are only limited data on the hepatic parenchymal response to radioembolization. Among the changes that are described in patients receiving lobar infusions are transient hyperbilirubinemia, ipsilateral hepatic lobar volume decrease with contralateral lobar hypertrophy (a phenomenon that has been termed \"radiation lobectomy\"), induction of liver fibrosis, and portal hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/151,152\">",
"       151,152",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The frequency and risk factors for development of these adverse effects, and their influence on liver insufficiency have not been well studied. These issues were addressed in a retrospective series of 260 patients with liver tumors (27 with HCC, 67 colorectal cancer, 25 neuroendocrine tumors, and 47 other tumors) treated by radioembolization, 75 using a standard protocol, and 185 using a modified protocol that included ursodeoxycholic acid 300 mg twice daily for two months, starting on the day of radioembolization, plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      8 mg daily for one month and 4 mg daily for a second month after radioembolization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/150\">",
"       150",
"      </a>",
"      ]. RILD appeared only in patients with cirrhosis, or in non-cirrhotic patients who were exposed to systemic chemotherapy within two months before radioembolization. The incidence of all-stage RILD was reduced from 23 to 5 percent by use of the modified protocol while the incidence of severe RILD was reduced from 13 to 2 percent. Disease-control rates were identical in patients treated with the standard and the modified protocol.",
"      <br/>",
"      <br/>",
"      Although the data are limited, segmental infusions may provide similar efficacy for appropriately selected patients, with a better side effect profile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/153\">",
"       153",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Radiation pneumonitis (incidence &lt;1 percent)",
"     </li>",
"     <li>",
"      Gastric or duodenal injury, manifest as severe pain during the procedure. The incidence is &lt;5 percent if proper percutaneous techniques are used. Pretreatment angiography is essential to identify and coil embolize variant vessels that may supply the GI tract.",
"     </li>",
"     <li>",
"      Vascular injury, which is most often seen in patients receiving chemotherapy",
"     </li>",
"     <li>",
"      Lymphopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/154\">",
"       154",
"      </a>",
"      ]; the majority of patients with have a &gt;25 percent decrease in lymphocyte count posttreatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456186191\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioembolization using intraarterial injection of 90-Y labeled microspheres induces extensive tumor necrosis with an acceptable safety profile. However, there are no studies demonstrating an impact on survival and no consensus as to the optimal use of this therapy. The lack of consensus as to the utility of radioembolization can be illustrated by the differing recommendations of expert groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      2010 Clinical Practice Guidelines from the AASLD state that radioembolization cannot be recommended as standard therapy for advanced HCC outside of clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      include chemoembolization, bland embolization, or radioembolization as acceptable treatment modalities for patients with liver-isolated HCC who are not candidates for curative therapy.",
"     </li>",
"     <li>",
"      An expert consensus group of the American Hepato-Pancreato-Biliary Association concluded that 90-Y radioembolization could be considered for treating HCC in the following scenarios [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/84\">",
"       84",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Downstaging/bridging",
"      </span>",
"      to transplantation or resection",
"     </li>",
"     <li>",
"      Portal vein thrombosis",
"     </li>",
"     <li>",
"      Advanced disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials are needed to define the safety and role of this technology in the context of other available nonsurgical therapies. There is obvious overlap with eligibility for TACE; it is not yet clear how to choose one technique over the other. A trial directly comparing radioembolization versus TACE in patients with HCC that cannot be treated with surgery or RFA is currently accruing participants, and the results will not be known for several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until then, even its proponents suggest that radioembolization be limited to patients who meet the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/156\">",
"     156",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unresectable primary HCC with liver-dominant tumor burden, and a life expectancy &gt;3 months",
"     </li>",
"     <li>",
"      An absolute contraindication to Y90 microsphere treatment is a pretreatment 99mTc macroaggregated albumin scan that demonstrates the potential for &ge;30 Gy radiation exposure to the lung or flow to the gastrointestinal tract that cannot be corrected by catheter techniques.",
"     </li>",
"     <li>",
"      Relative contraindications include limited hepatic reserve, irreversibly elevated serum bilirubin levels, and prior radiation therapy involving the liver. As noted above, at least some data support the safety of selective or superselective radioembolization in patients with branch or lobar portal vein thrombus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/140-142\">",
"       140-142",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Particularly in view of its expense, radioembolization cannot be recommended as a preferred first-line treatment for an unresectable HCC that is too large or multifocal to be considered for local ablation procedures such as RFA. One clinical scenario in which radioembolization may be preferred over TACE is in patients who are otherwise eligible for TACE but who have a malignant or",
"    <span class=\"nowrap\">",
"     branch/lobar",
"    </span>",
"    portal vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/9/41114/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457341266\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even patients who have a good response to treatment are at risk for disease recurrence and second primary HCCs. There is no consensus as to the optimal approach for posttreatment surveillance in patients undergoing locoregional therapy for HCC. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest the following after ablation or resection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging every three to six months for two years, then annually",
"     </li>",
"     <li>",
"      Assay of serum AFP, if initially elevated, every three months for two years then every six months",
"     </li>",
"     <li>",
"      In addition, all patients with underlying liver disease should be monitored and treated appropriately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important that patients with more advanced liver disease have proper monitoring for esophageal varices and assessment for treatment of their underlying liver disease, which may have a major impact on longer term survival. (See",
"    <a class=\"local\" href=\"#H457341302\">",
"     'Importance of comprehensive multidisciplinary care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361321233\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently occurs in the setting of cirrhosis. Disease extent and the patient's hepatic reserve dictate the therapeutic options. Nonsurgical methods of tumor ablation such as transarterial embolization, radiation therapy, and radioembolization are reasonable options for patients who are not candidates for surgical resection or liver transplantation, and whose tumor is either too large or multifocal for a local ablation method such as RFA. Patients with disease spread outside of the liver should be considered for systemic therapy rather than liver-directed therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Treatment algorithms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A majority of patients with HCC have underlying liver disease, which may be related to infection with hepatitis B virus (HBV)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatitis C virus (HCV). Furthermore, patients who undergo any of these forms of therapy are at high risk for recurrent disease and of progression to liver failure. It is important that all patients undergoing ablative therapy for HCC have proper monitoring and treatment of their underlying liver disease, which may have a major impact on longer term survival. (See",
"    <a class=\"local\" href=\"#H457341302\">",
"     'Importance of comprehensive multidisciplinary care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437042620\">",
"    <span class=\"h2\">",
"     Transarterial embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with large or multifocal primary unresectable HCCs that are not amenable to focal ablation, we suggest transarterial chemoembolization (TACE) rather than bland embolization alone, radiation therapy, or radioembolization (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1248650321\">",
"     'Primary treatment of large unresectable HCC'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Where available, TACE using drug-eluting beads may be preferred, although long-term experience with this modality is limited. (See",
"    <a class=\"local\" href=\"#H1248650349\">",
"     'Drug-eluting beads'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patient selection is critical to the success of TACE. We restrict this approach to patients with large or multifocal HCC that are not amenable to resection or local ablation, relatively well-preserved hepatic function (ie, Child-Pugh A or B cirrhosis), a good performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ), and no vascular invasion, main portal vein thrombosis, extrahepatic disease spread, encephalopathy, or biliary obstruction.",
"   </p>",
"   <p>",
"    Relative contraindications to TACE include a variety of other factors including, but not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum bilirubin &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Lactate dehydrogenase &gt;425",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"     </li>",
"     <li>",
"      Aspartate aminotransferase &gt;100",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"     </li>",
"     <li>",
"      Tumor burden involving &gt;50 percent of the liver",
"     </li>",
"     <li>",
"      Cardiac or renal insufficiency",
"     </li>",
"     <li>",
"      Ascites, recent variceal bleed, or significant thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest not repeating the TACE procedure unless there is clear evidence of tumor progression (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). TACE should be limited to the minimum number of procedures necessary to control the tumor. In general, we wait at least one month in between procedures if both the right and left lobes require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437042627\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The place of external beam RT among other treatment options for patients with unresectable HCC has yet to be defined. It may be a reasonable option in patients who have failed other local modalities, have no extrahepatic disease, limited tumor burden, and relatively good liver function. (See",
"    <a class=\"local\" href=\"#H1248650377\">",
"     'External beam RT with and without TACE'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Stereotactic body radiotherapy (SBRT) seems most applicable to patients with relatively small HCCs who are either inoperable or who refuse operation. Whether SBRT is a more effective or less toxic approach than RFA in these patients is unclear. (See",
"    <a class=\"local\" href=\"#H1248650405\">",
"     'IMRT and stereotactic body radiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Where available, proton beam irradiation may be a reasonable approach for patients with a large HCC and associated portal vein thrombus. (See",
"    <a class=\"local\" href=\"#H1248650412\">",
"     'Charged particle RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459409123\">",
"    <span class=\"h2\">",
"     Radioembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The place of radioembolization in the therapeutic armamentarium is unclear. It could be considered as an alternative to TACE for patients with advanced HCC who are candidates for TACE but who have vascular invasion or portal vein thrombosis. Although radioembolization may be safe in the setting of a portal vein thrombus, median survival is short in these patients, particularly if they have Child-Pugh B cirrhosis. Whether locoregional therapies benefit these patients above and beyond what might be accomplished with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    is unclear. (See",
"    <a class=\"local\" href=\"#H441999107\">",
"     'Large unresectable primary HCC'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"     \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/1\">",
"      Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/2\">",
"      Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Handbook for Reporting Results of Cancer Treatment, World Health Organization (Ed), WHO Offset Publication No. 48, Geneva, Switzerland 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/4\">",
"      Bruix J, Reig M, Rimola J, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/5\">",
"      Castrucci M, Sironi S, De Cobelli F, et al. Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization. Abdom Imaging 1996; 21:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/6\">",
"      Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000; 175:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/7\">",
"      Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/8\">",
"      Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/9\">",
"      Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/10\">",
"      Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/11\">",
"      Llovet JM, Real MI, Monta&ntilde;a X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/12\">",
"      Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/13\">",
"      Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27:5734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/14\">",
"      Brown KT, Nevins AB, Getrajdman GI, et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998; 9:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/15\">",
"      Covey AM, Maluccio MA, Schubert J, et al. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer 2006; 106:2181.",
"     </a>",
"    </li>",
"    <li>",
"     Hanks BA, Suhocki PV, DeLong DM, et al. The efficacy and safety of transarterial chemoembolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (abstract). J Clin Oncol 2008; 26:236s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/17\">",
"      Camm&agrave; C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/18\">",
"      Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/19\">",
"      Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/20\">",
"      Kruskal JB, Hlatky L, Hahnfeldt P, et al. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/21\">",
"      Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13:S211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/22\">",
"      Chung JW. Transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatogastroenterology 1998; 45 Suppl 3:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/23\">",
"      Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/24\">",
"      Shi M, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 2013; 105:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/25\">",
"      Brown DB, Geschwind JF, Soulen MC, et al. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006; 17:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/26\">",
"      Soulen MC. Chemoembolization of hepatic malignancies. Oncology (Williston Park) 1994; 8:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/27\">",
"      Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/28\">",
"      Solomon B, Soulen MC, Baum RA, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/29\">",
"      Trinchet JC, Ganne-Carrie N, Beaugrand M. Intra-arterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology 1998; 45 Suppl 3:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/30\">",
"      Yuen MF, Ooi CG, Hui CK, et al. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 2003; 97:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/31\">",
"      Stuart K. Chemoembolization in the management of liver tumors. Oncologist 2003; 8:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/32\">",
"      Brown DB, Chapman WC, Cook RD, et al. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. AJR Am J Roentgenol 2008; 190:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/33\">",
"      Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/34\">",
"      Plentz RR, Lankisch TO, Bast&uuml;rk M, et al. Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J Gastroenterol Hepatol 2005; 20:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/35\">",
"      Llad&oacute; L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/36\">",
"      Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/37\">",
"      Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/38\">",
"      A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome H&eacute;patocellulaire. N Engl J Med 1995; 332:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/39\">",
"      Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/40\">",
"      Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/41\">",
"      Doffo&euml;l M, Bonnetain F, Bouch&eacute; O, et al. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (F&eacute;d&eacute;ration Francophone de Canc&eacute;rologie Digestive 9402). Eur J Cancer 2008; 44:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/42\">",
"      Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/43\">",
"      Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; :CD004787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/44\">",
"      Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/45\">",
"      Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 2008; 112:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/46\">",
"      Georgiades CS, Liapi E, Frangakis C, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 2006; 17:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/47\">",
"      Pentecost MJ, Daniels JR, Teitelbaum GP, Stanley P. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol 1993; 4:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/48\">",
"      Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/49\">",
"      Uchida M, Kohno H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/50\">",
"      Sueyoshi E, Hayashida T, Sakamoto I, Uetani M. Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2010; 195:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/51\">",
"      Maeda N, Osuga K, Mikami K, et al. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 2008; 26:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/52\">",
"      Kim HC, Chung JW, Lee W, et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 2005; 25 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/53\">",
"      Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 2012; 56:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/54\">",
"      Chung YH, Han G, Yoon JH, et al. Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013; 132:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/55\">",
"      Sansonno D, Lauletta G, Russi S, et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012; 17:359.",
"     </a>",
"    </li>",
"    <li>",
"     Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo in combination with transarteerial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial (abstract LBA 154). Data presented at the 2012 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 19-21, 2012. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=87707 (Accessed on December 18, 2012).",
"    </li>",
"    <li>",
"     Trial information available online at file://www.clinicaltrials.gov/ct2/show/NCT01324076?term=TACE2&amp;rank=1 (Accessed on December 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/58\">",
"      Castells A, Bruix J, Ayuso C, et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/59\">",
"      Wigmore SJ, Redhead DN, Thomson BN, et al. Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury? Br J Cancer 2003; 89:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/60\">",
"      Paye F, Farges O, Dahmane M, et al. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg 1999; 86:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/61\">",
"      Chung JW, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/62\">",
"      Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/63\">",
"      Kim HK, Chung YH, Song BC, et al. Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001; 32:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/64\">",
"      Leung TK, Lee CM, Chen HC. Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol 2005; 11:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/65\">",
"      Wu GC, Perng WC, Chen CW, et al. Acute respiratory distress syndrome after transcatheter arterial chemoembolization of hepatocellular carcinomas. Am J Med Sci 2009; 338:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/66\">",
"      Kim JT, Heo SH, Choi SM, et al. Cerebral embolism of iodized oil (lipiodol) after transcatheter arterial chemoembolization for hepatocellular carcinoma. J Neuroimaging 2009; 19:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/67\">",
"      Kwok PC, Lam TW, Lam CL, et al. Rare pulmonary complications after transarterial chemoembolisation for hepatocellular carcinoma: two case reports. Hong Kong Med J 2003; 9:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/68\">",
"      Jouneau S, Vaul&eacute;on E, Caulet-Maugendre S, et al. &sup1;&sup3;&sup1;I-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases. Chest 2011; 139:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/69\">",
"      Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/70\">",
"      Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/71\">",
"      Vogl TJ, Lammer J, Lencioni R, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197:W562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/72\">",
"      van Malenstein H, Maleux G, Vandecaveye V, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/73\">",
"      Ferrer Puchol MD, la Parra C, Esteban E, et al. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Radiologia 2011; 53:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/74\">",
"      Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/75\">",
"      Gao S, Yang Z, Zheng Z, et al. Doxorubicin-Eluting Bead versus Conventional TACE for Unresectable Hepatocellular Carcinoma: A Meta-Analysis. Hepatogastroenterology 2013; 60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/76\">",
"      Prajapati HJ, Dhanasekaran R, El-Rayes BF, et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     www.AngioDynamics.com/pages/products/lc/asp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/78\">",
"      Martin RC, Howard J, Tomalty D, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/79\">",
"      Bower M, Metzger T, Robbins K, et al. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford) 2010; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/80\">",
"      Martin RC, Robbins K, Tomalty D, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009; 7:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/81\">",
"      Toyoda H, Kumada T, Tada T, et al. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012; 23:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/82\">",
"      Perrillo RP. Reactivated hepatitis B due to medical interventions: the clinical spectrum expands. Antivir Ther 2011; 16:947.",
"     </a>",
"    </li>",
"    <li>",
"     Bruix, J, Sherman, M. Management of hepatocellular carcinoma: an update. AASLD Practice Guideline. Available online at file://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf (Accessed on September 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/84\">",
"      Schwarz RE, Abou-Alfa GK, Geschwind JF, et al. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 2010; 12:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/85\">",
"      European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/86\">",
"      Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/87\">",
"      Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003; 55:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/88\">",
"      Seo YS, Kim JN, Keum B, et al. Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2008; 14:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/89\">",
"      Koom WS, Seong J, Han KH, et al. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys 2010; 77:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/90\">",
"      Liang SX, Zhu XD, Lu HJ, et al. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 2005; 103:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/91\">",
"      Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23:8739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/92\">",
"      Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005; 103:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/93\">",
"      Yamada K, Izaki K, Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003; 57:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/94\">",
"      Oh D, Lim do H, Park HC, et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol 2010; 33:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/95\">",
"      Mornex F, Girard N, Beziat C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006; 66:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/96\">",
"      Voroney JP, Brock KK, Eccles C, et al. Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. Int J Radiat Oncol Biol Phys 2006; 66:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/97\">",
"      Chia-Hsien Cheng J, Chuang VP, Cheng SH, et al. Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. Int J Cancer 2001; 96:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/98\">",
"      Guo WJ, Yu EX. Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 2000; 73:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/99\">",
"      Seong J, Keum KC, Han KH, et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999; 43:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/100\">",
"      Yasuda S, Ito H, Yoshikawa M, et al. Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol 1999; 15:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/101\">",
"      Li B, Yu J, Wang L, et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Am J Clin Oncol 2003; 26:e92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/102\">",
"      Guo WJ, Yu EX. The long-term efficacy of combined chemoembolization and local irradiation in the treatment of patients with large hepatocellular carcinoma. Hepatogastroenterology 2003; 50:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/103\">",
"      Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002; 25:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/104\">",
"      Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001; 16:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/105\">",
"      Lin CS, Jen YM, Chiu SY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006; 36:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/106\">",
"      Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012; 82:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/107\">",
"      Huang YJ, Hsu HC, Wang CY, et al. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 73:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/108\">",
"      Nakagawa K, Yamashita H, Shiraishi K, et al. Radiation therapy for portal venous invasion by hepatocellular carcinoma. World J Gastroenterol 2005; 11:7237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/109\">",
"      Yamada K, Soejima T, Sugimoto K, et al. Pilot study of local radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2001; 31:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/110\">",
"      Toya R, Murakami R, Baba Y, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007; 84:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/111\">",
"      McIntosh A, Hagspiel KD, Al-Osaimi AM, et al. Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer 2009; 115:5117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/112\">",
"      Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/113\">",
"      Choi BO, Jang HS, Kang KM, et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 2006; 36:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/114\">",
"      Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001; 19:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/115\">",
"      Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006; 45:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/116\">",
"      Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 2008; 8:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/117\">",
"      Seo YS, Kim MS, Yoo SY, et al. Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 2010; 102:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/118\">",
"      Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010; 10:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/119\">",
"      Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005; 11:3799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/120\">",
"      Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004; 127:S189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/121\">",
"      Sugahara S, Oshiro Y, Nakayama H, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010; 76:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/122\">",
"      Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2005; 104:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/123\">",
"      Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005; 23:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/124\">",
"      Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer 2009; 115:5499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/125\">",
"      Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 74:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/126\">",
"      Dawson LA. Protons or photons for hepatocellular carcinoma? Let's move forward together. Int J Radiat Oncol Biol Phys 2009; 74:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/127\">",
"      Kennedy A, Coldwell D, Sangro B, et al. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol 2012; 35:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/128\">",
"      Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/129\">",
"      Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/130\">",
"      Chua TC, Chu F, Butler SP, et al. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer 2010; 116:4069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/131\">",
"      Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010; 116:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/132\">",
"      Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998; 40:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/133\">",
"      Cao X, He N, Sun J, et al. Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer. Chin Med J (Engl) 1999; 112:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/134\">",
"      Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000; 41:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/135\">",
"      Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/136\">",
"      Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/137\">",
"      Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009; 19:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/138\">",
"      Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/139\">",
"      Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/140\">",
"      Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/141\">",
"      Salem R, Lewandowski R, Roberts C, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/142\">",
"      Tsai AL, Burke CT, Kennedy AS, et al. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/143\">",
"      Woodall CE, Scoggins CR, Ellis SF, et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 2009; 208:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/144\">",
"      Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/145\">",
"      Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/146\">",
"      Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/147\">",
"      Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/148\">",
"      Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/149\">",
"      Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/150\">",
"      Gil-Alzugaray B, Chopitea A, I&ntilde;arrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/151\">",
"      Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009; 16:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/152\">",
"      Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 2008; 53:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/153\">",
"      Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011; 79:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/154\">",
"      Carr BI, Metes DM. Peripheral blood lymphocyte depletion after hepatic arterial 90Yttrium microsphere therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2012; 82:1179.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trials information on NCT00956930",
" available online at file://www.clinicaltrials.gov/ct2/show/NCT00956930?term=radioembolization+and+hepatocellular+cancer&amp;rank=1 (Accessed on December 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/9/41114/abstract/156\">",
"      Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15589 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41114=[""].join("\n");
var outline_f40_9_41114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H361321233\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H361319942\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361319949\">",
"      Treatment algorithms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H457341302\">",
"      Importance of comprehensive multidisciplinary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H361320196\">",
"      ASSESSING RESPONSE TO LOCOREGIONAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650293\">",
"      TRANSARTERIAL EMBOLIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H361321044\">",
"      Technique for TACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650307\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650314\">",
"      Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650321\">",
"      - Primary treatment of large unresectable HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7665170\">",
"      Selecting candidates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H43986409\">",
"      TACE plus sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650328\">",
"      - Prior to resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650335\">",
"      - Prior to liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650342\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650349\">",
"      Drug-eluting beads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650356\">",
"      Issues related to hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650363\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650370\">",
"      RADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650377\">",
"      External beam RT with and without TACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650405\">",
"      IMRT and stereotactic body radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650412\">",
"      Charged particle RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522744318\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1248650419\">",
"      Radioembolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441997251\">",
"      - Iodine 131- labeled lipiodol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441997270\">",
"      - Yttrium-90 labeled microspheres",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H441999107\">",
"      Large unresectable primary HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H178682735\">",
"      Use in patients being considered for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H441997277\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H456186191\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457341266\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H361321233\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H437042620\">",
"      Transarterial embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H437042627\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459409123\">",
"      Radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15589|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/37/41567\" title=\"algorithm 1\">",
"      Treatment algorithm for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/36/11855\" title=\"algorithm 2\">",
"      Barcelona Rx algorithm HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15589|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/51/7996\" title=\"table 1\">",
"      CLIP score for HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 2\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 3\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/46/28396\" title=\"table 4\">",
"      Modified RECIST for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 5\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/29/21978?source=related_link\">",
"      Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_9_41115="CP symptoms PI";
var content_f40_9_41115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cerebral palsy symptoms at different ages",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The symptoms of cerebral palsy change as babies grow older. Possible symptoms from birth to age 2 are listed below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A baby younger than 6 months might:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have&nbsp;trouble holding up his or her head when picked up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have a stiff or floppy body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stretch his or her back and neck away when being held. (Your baby might seem to be pushing away from you.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cross or stiffen his or her legs when picked up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A baby older than 6 months might:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Have&nbsp;trouble controlling his or her neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reach with only 1 hand and keep the other hand in a fist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A baby older than 10 months might:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crawl by pushing off with 1 hand and leg while dragging the other hand and leg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not sit by him or herself",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A child older than 1 year might:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not crawl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not be able to stand up when holding onto something",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        A child older than 2 years might:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not be able to walk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not be able to push a toy with wheels",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41115=[""].join("\n");
var outline_f40_9_41115=null;
var title_f40_9_41116="Conditions associated with elevated chromogranin A";
var content_f40_9_41116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with elevated chromogranin A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastroenteropancreatic neuroendocrine tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal tract (carcinoid tumors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic NETs (islet cell tumors*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Endocrine disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary thyroid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic atrophic gastritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatocellular carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritable bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute coronary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac insufficiency/failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Essential hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant cell arteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proton pump inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histamine-2 receptor antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway obstruction in smokers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic bronchitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic inflammatory response syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency/failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-gastrointestinal cancers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate cancer&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small cell lung cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroblastoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Eg, gastrinomas, VIPomas, somatostatinomas, glucagonomas, non-functioning pancreatic neuroendocrine tumors.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Even with a normal prostate specific antigen level.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Modlin IM, et al. Ann Surg Oncol 2010; 17:2427.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41116=[""].join("\n");
var outline_f40_9_41116=null;
var title_f40_9_41117="Teboroxime and coronary flow";
var content_f40_9_41117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow estimate of teboroxime",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Composite of the fit functions for the relationship between apparent myocardial blood flow and the true myocardial blood flow for teboroxime, thallium, and sestamibi from separate and simulataneous evaluations of the agents in rat single pass experiments. The early uptake of teboroxime is proportional to flow up to 4.5 mL/min/g, a level at which thallium and, particularly, sestamibi underestimate true flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from Di Rocco, RJ, Rumsey, WL, Kuczynski, BL, et al. Measurement of myocardial blood flow using a co-injection technique for technetium-99m-teboroxime, technetium-96-sestamibi and thallium-31. J Nucl Med 1992; 33:1152. Copyright 1992 American Heart Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41117=[""].join("\n");
var outline_f40_9_41117=null;
var title_f40_9_41118="Squamous cell carcinoma of the distal esophagus Endosc";
var content_f40_9_41118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic appearance of a squamous cell carcinoma of the distal esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 208px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADQAPwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5klkfzX+dup70zzH/AL7fnRL/AK1/9402gB3mP/fb86PMf++3502lVWdgqKWZjgADJJ9BQBNbJc3VxFb2yyyzysEjjTJZmJwAB3NelL8CviYyhh4dlwRnm8hB/LfXvH7N/wAGl8MW0PibxPbg67Muba3cZ+xoe5/6aEfkOOua99lkWKNnY4AGaAsfBDfA34lIwVvD7gnp/psH/wAXTZPgj8SIhl9AkA/6/If/AIuvtpJFd3nOTyTzUNzM8w3AnHpSbsdcMNfdnxDJ8IPH8Y/eaLIP+3qL/wCLqnJ8NPGUTbX0tt3oLmM/+zV9hanLPd3H2e1zj+Jqz7rR5lIMXDDqfWsnUfQ9OlldGS9+TR8mj4a+Mz00mX/v/H/8VTZPhx4xiGZNLlUe88f/AMVX1ZcpdWcO50XC9SetYpLai/8ApBYLnhVFJ1WjVZPRe0nb5HzXD8OvF85/daa7fS4j/wDiqsH4W+OBwdIkH/bzH/8AFV9LpbCFF8tSq+4rRsp/M+STB7U1UZhUyunHWMmfK4+FnjcnA0iTP/XzF/8AFUH4WeOAM/2RLj/r5j/+Kr6ouD5dwFTAJ6ZNSOrGMkMQ3vWlzH+z492fKB+GXjQddJk/8CI//iqYfhr4yB/5BUn/AIER/wDxVfTlzO8c4Ei/LnrSzBWG5GOaXMV/ZsO7PmBvhz4wU86XIP8AtvH/APFUw/D3xaOumyf9/wCP/wCKr6WlZ0cBlLD1FRyt8ueMY6Cp52J5fBdWfNTeAvFSnnT3H/bdP/iqa3gbxQvXT5P+/wAn/wAVX0JMMuQwI75qo+CMqeRR7Ri+oQ7ngbeC/EqnmxkH/bZP/iqifwl4hQ4azkB/66r/AI17td7lQsqkkc1jSMZjvGRg49xS9oyfqEe54+3hjXl5NpJ/39X/ABqF9A1hfvQOP+2i/wCNeuXRxkjGRWZNtZMt074HWk6rQfUYdzy2bTtQgQtKjhV6/OD/AFqj5j/32/OvQrmNCx6kA9K5PW9O8t2nt1/dk8gdveqhUvoznrYXkV4mR5j/AN9vzo8x/wC+3502itTjHeY/99vzr174POx8N3eWb/j8bv8A9M468fr174O/8i1d/wDX43/ouOgDyOX/AFr/AO8abTpf9a/+8abQAV9Xfs0fBn7KLbxf4stv9JIEmn2ci/6sdpXH970HbrWD+zX8Gjqstv4s8VW3/EvQh7G0kH+vI6SMP7o7Dv16dfrkDAwKl3bt0BPsBOATVA2r3JLTkhSeFq/TJXWNdzthRVFRbWxRv7MNCqIwjiHXHesG6kUMYojhRxmptc1cFSEzt6AetYaSt96bgHoKylPU9bCUJuPNItQBIT8gGT3qK8ufIiMjcADPNQtfxKCzdug9awdVvZJ3zL8kPYGouehGjKT2KGr302oOVTKRDqfWq0d81sm2OMbR3NJLe/aZhbWcZbPG4dK0rbSY4Ii14SzHoKzcrs9DljTjZklne2tzGA7Dd3FQXkKiQPC5GDzjtUV0sNtFuht8HPWp4bmOeIAKWYDnHam30OZw6rYLtra4gQO5Ey9wetVUu7iF/LdDIp7+1VJCRcEZC+mRWxaOrICy5cD1ouyHZLUrz2yTEOHI9Uqq8saHG0gjitCaSJ5FZfkxwapXiKwYoQc8564rSzM3O+g1I5JAXijZ0UZLAEgVgTq63bfvMI3atg6xNaQGK1Zd5GGBrnZoriKZnkbeHbdmpYkmTSyBTg1VmjG7OPwFSznIAYZ9MVGxYx/LkelK4mijc8gGNyD6HpVCTggOCuevFaXJ5baSPWqFwweXBGT09qm5LKMkZkV9hyF7DvWHdyBSV9a6Xy1gaSKQ+WXGUbHQ1zl9KJZTvUAoCCc8E0rksxJk5zj3BI6VRkYv0yR05HX/AOtV28YfdTKnGSetVkRepGCx9TVRTOWq9bI5fV9Oa2PmxgmI9f8AZNZdd20S7WDAkEEEckYrlNV09rSUsoJgJ4bHT2NdEH0POq07e8jPr174O/8AItXf/X43/ouOvIa9e+Dv/ItXf/X43/ouOrMDyOX/AFr/AO8a9X/Zs8C6b458dSR60S9lp0Qumt8cTncAFY/3c8n16V5RL/rX/wB419C/sWf8jxrv/Xgv/owUAfYEUaRRrHEipGoCqqjAAHQAU6ik3AHB4oAGYKpLHAFc/qd75m7ugzjHep9augUMYfbjk1zTXG84DZFRJ2PRwmG5veZnyPLLegbdxzwPSrTo4P70YHYVoxm2toTI5G4+tVJysp8yUn2UGsbHqqrd2S0Rk3EMUZMkhJPYZ4FY1wovZjEfu98Vpa5cgDbEvzY5xVa0aOCNTIp3MMkis2dtNu3MXLGxt7KIFQqn1NWHRruDdGylAev+FUykcyu0rHb2rHGsmW4axtGKBOpFWrIympTZ0rxW06KsyjcPTvWLNpU1vqX2q2ugkWMNEehqzbFo8l2+X1qPUXhmhK7sHPbg1LSb1MlKUHYqSqHmJYAN16daekqq/wAuMjt61kT6gYJNgbK9PWp7e5VyGABzSHK7LF04kG5ARk9OlVH3x2cu5QW6VejVZlAzg5yQKqXjmOGcuACP5VqndGSkVrnS3eyjkgbE2MnnrWOsyMXjlBWZDgqa6JJt1pG6FsgZrnLp1ubiWVfkccAjvWbNFK+gkjb1BICkcZxVdpwqdRnp7U+Fi6Kr8Adc1C8UayOFI+bnaaAaZBLGvl7l656Cq0i9Nqgkn6VedcJjI4qnuKyKSQMHr1x9aLGTKGoXcSLNHISQV+UnqprjpAR8zMcsc4zxWzrtwjXsqKflB6Z4zWDcOV3NIQMAnGam1xPRFRkZ5jg7gDjJ4xSnBJClTjjI5qSMstthiQD0U4PNCBQARnPT5RWqOCbuyJxnhSMgc8YrY0HSkvbeVbqHfDKNpB649RWceRwNzDgDvmu70a2+z2MKsDuAycetUrpkNHhviCwXS9Zu7JHLrC+0MRg4r074O/8AItXf/X43/ouOuA8eHPi7Uv8Arp/QV3/wd/5Fq7/6/G/9Fx1vuefJWZ5HL/rX/wB419CfsW/8jzrv/XgP/Rgr57l/1r/7xr6E/Yt/5HnXf+vAf+jBQI+wWcIMsQKp3E4OfLIz0qrdymSRiWwq8VTE2cDIxmk2dVKhfVnNazb3t1cudxEQPr1pLCFlIEnatrUpCABHySefas+4dYULDHHJzWEtz26NR8nKkQ6n8u0qOnQVnT3TMu1vvDtWdeamZps7jtGRjNZ51MNO0aA7h1zWEpandSoPlVxxuJPtR8zGCak1K7mwot487f4jWXd3ah8g5PrWbf6nIYXBlwccAUuc6PZ+Qa54muPksLbBupOCR/DVvSzHZIodi8x5ZyeprmbIQwM87Za4Pc8n6Uk0l2X3sypH1ANRzNsUoqK0O4bVgABkE9gKqTXxYEHOfQ8VyKalIpxDEZGHU54qGS9uBIGmZAx6AHIFbJnDLlTOlMq7Wx39eamtJPLjHuOK5YXc7qGd0dRyQvU1ow30YiDbWCf7RqbMzlUVrHSW14Y5MkqBTNUlSYg5zngjpXOPqEMhADBOevPNW4mdpojbBZ0bqrH7p9a1i2jBb3Rs2twgtGQnAUYx3xWDbReaJpgcRbuB3reSWGQsg2+YvDL0Iqsywxs8a8ZHSm1dFxmluYl0ytmOIF2PUUyAeWoEoyfXuKmAaOSaVUKqvHtVNblxOzldw9u9Fi3ImuZFVDnmsa5uXEm5WAC9vWrN9fqVHy4JOOlZs64hWUsMnOVqWyUkc7q8RdvMUEMpyay7olyqpyxIzmtu/BaJ0QcvwOa53zj9pYocgfKCKmK1M6skokqkfaM55B5qVWMagMzZ56H+VVkYg/fKn0Arr9C0YRxJNdKHmbBVCPu1ocS7kfh/Rg4iursE5b5UbqBXX+Uo4DEgcZ9RTCn2dIzjcRywxjFWFwckDA9KpA12PAfHgx4u1If9NP6Cu/8Ag7/yLV3/ANfjf+i464Hx9j/hL9Tx08z+grvvg7/yLV3/ANfjf+i462R5s/iZ5HL/AK1/94179+xs5Txvrh7f2eM/99ivAZf9a/8AvGvcf2S51t/GGtM5wDYf+zihuw6ceaSR9TXFxukKKTyant4mMZcrwOlZ2lss8pkYADNbLTr5RC4ArO6ep69RcloRRnOyhXY/ePHNcrrk0rSqinCHk+9dDcOGBORnPHPWuZ8Qq0Do3BH1rKex2YZJPUxWhRVLHq3rVXhSRsAyfTmprmT5eeaqPLsO4gkDpx0rme57ClYjuYCqlyB0rJvrbK7wAe/0rWublJYsyNwBWNeXRmUrEdgPcdhSsZTq8pg2EDjUJtjEnqwJ4FWrogKWkfIB5OaluJHii2WyEn+Jj1PvVW4ntCgjQs8/8R7CtFA4a2Ju9ByM5TMabVA78ZqmYi25rkjaT8qL1/OrzShQGZ1LYwoxnFU7uc72E0qx7Rj5yAPwFbJHFKs7jIVjLjY3lY5w3Q1de1aVNsDNk9lO5azWuppowi3caRjvsAz/AI1nwRazGd0N+YRuyuEADD1oI5m9TYvYbiALvsyCM/NG2PzB4qTTPtNvNHdW+BKhyyZ+8KzP9KnlLXd0ZnUZbfxj3AFWtNkilk3LcBmB+UxtyPaiwlJnaS3q3dmLmADzwcsFHP41Wub1RLG7qUdiBg1htcXEFwJFy+fvHp+daEWsQzREyx7pl4wRkCruzWE11Ni6uIrizmhVsFh8wHU1hNMFUqu4oBhcjnPpTZLmJSXO4M3A5pLWQRTCRnQ7AThzRJ3K5kjNdiZbhLuNklXaUQjHHrVKY5LA5BPHStC9vR5CNNzMfl8wnJZfc1mXlzFa2huWXc38K5wWPas2h8+hia1ePaXCwwACQrgt/czWDjYUCnc7HAXGS1SySvO7XMxBkZs4549q6/wDovmq2r3MYPOy3BH5tVRjY451Odk/hjww1qi3epoDdNhljIyI/T6muysLSNULnJ9yOpqwIchFwSOuT0q0m1FALAeo9DTSDc5+/jljN3K/KggL9KlTG1WIwpFXrpNyPGefbtUCptjC46U0insfPfj3/kbtS4x+8/oK7/4O/wDItXf/AF+N/wCi464P4hjHjPVB/wBNf6Cu8+Dv/ItXf/X43/ouOtlseTP4meRy/wCtf/eNev8A7MzlfFWqgD71mB/4+K8gl/1r/wC8a9Z/ZukaPxZqOxclrTHT/aFKfws2wn8aPqfUmnz4t3K5GBxiquta4LOEojbpMdAelTQq0VuAOWPNchdxrLez+dLt3tjPtXG5NI+pp0Y1JtvY2YtZjKrG0gDkZIpmoMLllDtketc5LYXNhL9ogkSdB1Ddall1EmQZIUH+H0qYyfU3nSjH4B+olUIA/wD1Vl3M+yIYcBMHIPc0ahqkMMbhhnjJNchLrCTSdSMtsUepqnrqZe0saizyXGIUJEY6s3SlNxaREKrKxBxwazA0krtCu/afTvVyzsFtz5roox155pRj1ZxVqje5nX95JduYFXbF0LK3J9qrtZ/ZYAzAoMgA55P4d60I47eJ5Z2wTnKqaq/aHuZnaJcugJ3NxHEPXJ6mtTilUtoilcSjeEldwQPury7f4VUiSFZWl8s72PQnP5k06MiSQzxguG5L7tzN9fQe1Qx3CBy5I5OSjDt7UiI6ln7VErs2QJ8cmNcj8/Wo2e4kwfNY9iJD84/CmtcLIf3iMEDb1GBj8qfJdozJJdyiNj0DqVI+nFUXsSI0trwq7cj25qGBhFM5mVgGOSUXIP5U2O+shO0QEgYjhpWBD/TJyPxqS5kR4S1vgkgBtrcH2FMnVFoauIF2yfOvUKTn9aZDqtnK77bhYAwJy2SP06VR8lRkKGEmeg5/Oq95La2Q/wBMuIbdSMjDAt+XWjUXMuptWN7bM5L3oaUEbSV+UD6VLOLPDOs/nbuSyg4z6VwWrazFOix6X5oOQXuGO0n2X/Gol1O8ZP8Aj9mXtkDOKaTJVeKdjq5riG2IedHEKtwrnBY+grBv72S9ummlUogH7uNTkKKzY2Z3Y3EjyyddznJx7VYZseXtb7w6etHLYmdd1NELtMn7sN/rGwOO9e46fZra2lvAh2pBAoAA6HFeJ24VLm0cjIWZWOB23c17pHKyhW2jBPcdvSmtyU7aFlo1jIIwQo4BNMZVIZnjGG98/jUo2LlD1x+VRzEiIMmMMQpJ7U2uxsmVZgGY7QcAYzVOUgKA3UelaEzlQ2Me9UJmUlRjrzUpg7nz38QmLeMtUJ/56f0Fd58Hf+Rau/8Ar8b/ANFx1wfxC/5HLVOMfvf6Cu8+Dv8AyLV3/wBfjf8AouOtlseZP4meRy/61/8AeNeq/s6SiHxZfsc/8ev/ALMK8ql/1r/7xr079n848Tagc/8ALr/7MKmfws0wv8aPqfVUUwnh4HIrj/FsZ2FlIRlOc+1aFlqQSIxdGPGTWPr0c8kcmWzkZFcZ9RFOMro5K41i5QbUlyfu4HWrNnPMYi8iMo6ZkqfRdDVojcGQeaT1PIq3rjRw2wjlIclafJct1lazOZ1i6RVdA3mMBkkdB7Vl6bpstzcJPPlEj5QdCa1PsrcOGXZ2XFbNjp4+Ri2T1p7aHLUqlWRDbKktsodgMYaqNxcSMHRgTIBknPyrW7fIkeSzDCjgDgZrkPEd95KeWmSW5JFI4ZzuZuoXWHYRKXyOx71Dp+ny3xxced5R5EanAPufaqqSO4d5WznjAHStq0JgtlbzRC5HBAq0c83YWeFLVzbx4wIyzBmxnHp71gCW2uQPstxtZuSsnyn8M1ZFm1zfNJNcsdxwW3AH9eKpalHp7TlFAl8vndvyB/n2qkEKnIS/aZDIYrOESsvzO4YAJ9X4qZYbl1z9pjYv/wAs4yW2/n1rAaYLMTaRPn/ZbaPris19Y1Lc4t7ySGPOMIRz+YqlFiniLHX3CgAAgyZ6h1GBXOX2rPDIYLE7ynBdsbQfQAday5bi7uFInvbiQd/nIH6VEoAXAwADiqUDCeIb2NCbWdRmg8hp44E7+Smxj+NUY41QkgZYnqeSaBkg/wA6XJ6ck1SVjFyctyRW28ZB/CposEcnGe4NQr8zDHT2FSpgMAV3EdvUUwROrEY+YdMc81YtAWhOFX5TkEdahwp2tGT2+X/69aGip5sd3GeqgEYqWrmqZZEBZbhdx3JDuH1HNez2LYsbTzFMgeJGLA9CQK8qsUDxzoV3EwE5H8Vel+Hbn7V4dsZBIQzQKuAM8jg0GyepowQGG5uJGk3pIRgY5FTOEPKjK55B9abHId6qjj5ecEdamlC8blGTzx60tDW5TvDhsx4JbqKzmyW+dcdhWheYQ5APJ5qlKSSB0C81LQz56+Iox401UD/nr/QV3fwd/wCRau/+vxv/AEXHXB/EIlvGWqE9TL/QV3nwd/5Fq7/6/G/9Fx1stjzJ/EzyOX/Wv/vGvTPgG23xNf8Ap9l/9mFeZy/61/8AeNei/A1mTxLeMpwBbc+43ClP4WaYf+LE93BEsm5SQRTNcnaIQjdyw7Hg0RSDzlYgbfX0q8NEm1G7jiVfNwdwP90etcsFdn00ppGDo8pF7hHfyyMlW7H2qrrCma/RnVuuMV1X/COS6XcTNdS+buOcL2rl9XMsOpiOQhUcfLiqkrGEqiew0W7SkmMDA/hNbEPlpAu7jA+6ahsx5FuNys57EVO0gTAjX74ztPOKhI5pyMq/lSfKpjae3pXn3iOX/SHjKYZSRjrnHSu9vMhpScbsYwOK861xkg1SRpCV9SeRzSS1OaTsZ1sJiU8tSowDz3qaW8kE6xK8isTtLBPMf/gI6fiarwvLcSkY98scD/8AVW/o9usTefJKDIuRlV4x9K1SMWzD1G2FtsRr6WYkbisqADPpjqaqSgmQCWNipGQQAVH+FTeJbl11gSNBhdh2F/uge3vWa3I86UlF7KTzVpLqK5FfzxRiVYV2kjAGelZaDAAPOPQVLdTmdwcEKOnaoucc5J7Crsc85XY7JwRweelB4/8A1ZoGCOv4CpAvrk/pQTuMCk54A/nTsdM9afznHO30oXkgBevFA7CxghgSMjHrU2/Cg7z6e1Rqu3Ofl/pQpKnGA2O2P1oZS0LCqQCADjGfxq7pdyILxZCG+Y4c56iqCEAjHQ84NXNPtnmcbVJOQfwoKW51mnJ5Vxatldkjsg+b5cE9+9dP4TuPsxudPL8ROWQZ6jNc5p9uXULIc4JK4zxV1ybe6S4DHeOp9RUs2Xkd0HAkUuQAehFTPM3l5VlLY4ArCtrwS4ZSNrrjNaFjcFXRDt8scMe+Kg2T7ltRvU7sFsdaqXOfKPr0qxDcK3bg569hVW5lCjBIwf0oHc+efiANvjDUh/00/oK734O/8i1d/wDX43/ouOuC+IBB8Y6mV6eYP5Cu9+Dv/ItXf/X43/ouOt1sedP4meRy/wCtf/eNejfA6J5vEGoCPqLXP/jwrzmX/Wv/ALxr139miES+LdUzg7bLOD/vilJXRVF8s0z2vS4xHp4V1DP3BFdVoBW3HnYAbGMZ7VzupwSQbnjHB449KzdCutWu/EDWkBxYKvzk9c1ilbY9icnNXOm1m+Blbf3NedatcpeeI05/drhT6V2/iKMRMy8lcfePavOYhLE0rKm4GT7569amVzKmrLQ6qOPy4nwdxbjGMVSSFo8mTO7PGT2pbDUJLhWVQCR2/wAatSxosDC5wSw6Yz+VTbQTuY+pEpYTSKCWA4OM815d4yvlbVLdERvtBQAoMZ3CvTtUZ0gIjyBjO0dOK8Wnlku9cmug+5g5Ck4H1oitTnm+xs2sd0EB8ny1643ZOfXHetizvUWJPMVh6sy4GKwL25kigbyppEdl+UMBkU2xjlnGPttyExykgUrn/ZwK0tfUyb7h4wnkuZ0YITFjCIOMH1+tc1OXY7JCSAOnvWjdOWvJHmGQpIRx0IFZbsHdmA4b0H61aViJSshoAwQMA4oXjkYPuKBz07d+1PHzDuQe4FWY2HZAPX04pykA5xwP0pFGDjP8uKcgJYquCevXFBaFC4U4PXrjvUoPzKgXcQOlNXp8uTnt0zUyFBJGJPnA5I/pSKRGoeSTylfAHX/CgqN7DBxnjHarRk/dqVgCDAIIODVUEZOR09adwsWFzIu3r/Oum0K0PlhsZ9yeQKwtKjM9wkYJ57Cu6t7dIRgZB256VJaVyS2UKmCW3diePypJVEgdtx+UYA6VKQXIOD+NPSLcyjJIzzUM0joM0uJTc7ElaPHBB6Z9q6N7QqiMjAt1OKo6faj7WWZM8ciukVRtHGDUstSZkO0qD5jznp61DcuU/wBYF57A9K0rtdkZ+UHkH3rNuo4mKhAQP6mhFXPBfHpz4t1Ej+//AEFd/wDB3/kWrv8A6/G/9Fx1wHjxdvi7Ul9JO/0Fd/8AB3/kWrv/AK/G/wDRcddC2PPn8TPI5f8AWv8A7xr2f9lkqPGOr7s4+wdv98V4xL/rX/3jXr37NMnl+KtWPrY4/wDHxSnswj8SPoK/ljmkIySACOO9SaRZraWryxqQ7HqBzTLERvEWbBJPU1aMxgZVJIicjPPQ1zxkehzWVkZuvwtNsV8jd1rm4tL+V1YAqCSD612+uZUoAQxIyCelYXnoFLSsFPcClJjjIxbeH7KxlZAqt8qkdxU2pbVVTuQq4zgelVL6dftARSoiIySe1UrqYG3AgDFUOQSM5oeo7lfVrmKCxuHbBQITn8K8Lt5sxM5wC7FgAOleneIriSewuwCDuDfLjoMdK8pgIaJcZx6CnTTMKzsaIPmLueVg2ccmrCNJMoi8zci9B1z9aywWx0yfer9pdrEuWBz1BHArVGGjK+qtsQIFVW6ZqgSAentU15ci5m3IAB/M1EBwAOtUS9WCjd0JNPOem33poGBnHTrSggDH/wBfFCFsO2sRngD0ApOMYIJNAyQc8H34zUq4AHQE8+tCGiRT8qjy8rj04NJuIyVU89ye9CMMkISe9BUAZOcHt0zRoUPSRwTsChiMY74NNXIIADEnjA7Um8EADAPb2Nbml2MMckW873PzM/8ATFIq19i5oFnJaM0syjzCPlCjtXUW5MpUg5rIRmuJUSBCcDnkYrpLa3NtGq8bhyRUtmltNCZIFGGbJPYVZgtWAyRj8Kv6Vaeanmyjg9BWotqCQQMAVm5DRW061LkOwI7VpSwFEFLZFBKwJAPvxVuXbICOMUJjvYwbn7rdvfFZsy4HzD8jW1fxhQcZzWJcE44Uj+tUht9DwLx/j/hMNTx08wfyFd98Hf8AkWrv/r8b/wBFx1wHjz/kbdS6/wCs7/QV3/wd/wCRau/+vxv/AEXHW62OKW7PI5f9a/8AvGvVf2dm2+J9T97P/wBmFeVS/wCtf/eNeifAvV7LS/FsqX8oh+1w+TEzfd35BAJ7ZqanwsIfEj6a0zAUgZOeabqtx5ewbSwbKkjtTbQGMkEYPX1qJ0YyFtx254BHFcUZHoWuyv50x/dux9MnqKr38Q2A52v79GrXS23EvkEnk57UrxJNEUcA+9Xcq5y0OmpKHe55Cg4UGq11b3UdgRbziKIMCQud7889q6aRFUGKOMmRRkLjrRpWBKxZODxtPI/Gmn3A4R9CkW9KX+2RGzkqwb9R1ryPxf4cuPD2rTogeWxkbfE69QD2NfTurQqIhLbhBt/gA6Vwmr6eLyUrdQ+ZCT90jp9KOflehnJc6PENF0vUtbvEttLtXd26yS/IiD1LGusk+FOufZ976xopcfeiEjHH0OOa7ZNDFtHi1ubmKLtGTkYqRbfUFBMHlzL/AAh1wa09oYunY8wf4f68u/y5dNl2/wAImIY/gRVG88Na/Zxs82kzNH1LRfNj8K9Yea5gcPf2rHtlORV7TpUuW328sT4H3ZSTzS9qyHBHz606qSHVkxwQ6Fan3qVzgEY7V9CXsslzE0OpW9s1u3ykGIMp/SvM/EPgqBZTLoFwsG45MEvMf/AW6j6GrVVMSgcVhjg4IHuKkSPAJdQAa17XwxrD3iQusRkPGUbdgV1Fj8P5AynULpAOu2EHOPrVXGo2OD3eg9gB1/KtbTNClvHVrnEMR5+b7zD6V3reFNIgQeTabmX/AJaSuSasaXp0ME6sASueQelJtDSsc1/wh32kr9it41x/G3H863dJ8BSsUe/uzIRz5MXA/E12VtayOMhdqY4rQgc20RO04A4PrWLqM1UdDnxo8OnxyRmBFQDIC9j9e9Ult3nkCdyRk/0rf1JZDIrSOxlHJX+EE9qILVNmUbcR3x39KE76jaNmytDHAq/xbfwqO7UrG+0janX1PtSWt0AjLIc84AzUVy/mS5foeAKVr6iV7lQuwbKjk9qebzylw2M+wqKXh2y2fQZ7VUd9joxUlc9M1Sjcdwv7huCwwG96zp2DISeh4Ge9LdXBMhbOVAIUGqVxcAJudlSONckk4A9STWqVlqJnh/jr/kbNR/3x/IV6B8Hf+Rau/wDr8b/0XHXm/iu8hv8AxDe3NsSYZHypPcYxXpHwd/5Fq7/6/G/9Fx1ojjlueRy/61/9400HHSnS/wCtf/eNNpiPoP4LfEf+0RDoeuTD7ag2207n/XAfwn/aH617FLgjg5U9q+HI3aORXjYq6nKsDgg9iK+jvhD8QT4it10vVJVXVol+Vm6XCjuP9od/zrmrUdOaJ0wrdJHqKyPGwCRhgfepLkFgCkR/2tvUU6DIPKg1YOCCBkcfdrmUzobMmeVAAsKkORg5/wAajgRweR71bmUHqMt70R8HJxSbKTuSNGGQZxk9qbJZRzfKIwD3ZiABVmNcDI5q5AsTKTMpZO4VscVKlcl6HH3ViRIwSNZlHIYHiq28xEB0ZSOyjbXYXFlCkgliZ4oicqg5H41SurCKUsZYwCejBuDVom99zDdhNFs3KR12sBmsC80u3D+bEqq3f0rpJtNKcxMHUdOeRVV7QqSVDD3FUm0LRnPAykbFBPvjIrJvLa4ZfkVSOxHSuzW0+ZSDg9CcVVvrB/O8sIW5464xVxt1E4tbHJW8tzbjaEYCtCHUJCdjJhj3rbgs4XlxEyyIB8zHoDUqWSpMAShQ5wNvNWKxkpFJMRxx3z0FaVlpwBDP83PWrqxohEZjX2wKvxqgUEjBHp0qWylGxCqNGM9FNK5UFSyNI33gAfTuac8gLhmwMe1VZ52nLxpwp6n1FSkU2U/mu7pnnYde39BVwMinZGDtHYnk1BbwkMzEHGeT/SnI24szHOfbFaWEmTM4woCgAdNoqCZx5qLuPXovNMmfy4iWOSx4ANV1lKMcqWLDjHUe9Uok3FuJCZNq4VD7/nVK4k82Ut/BjgA9Kicgu7OwyTk1UlctkLkDrzWiQr3EuCMHJwAOteSePPFRv5GsNPf/AERTiR1480/4fzq98QvFnmeZpemv8g+WeVT1/wBke3rXnVXymE5vZBXr3wd/5Fq7/wCvxv8A0XHXkNevfB3/AJFq7/6/G/8ARcdMyPI5f9a/+8abWpLoOseY/wDxKNS6n/l1k/wpv9g6x/0CNS/8BZP8KAM2prO5ms7qK5tZXiniYOkiHBUjoRVz+wdY/wCgRqX/AICyf4Uf2DrH/QI1L/wFk/woA+mvhP49tvF+mi3vGWLWbdf3sY4Eg/vr/Udq79sjpyB3FfGejWniTRtTt9Q07TtUhuoG3I62sn5Hjke1epf8Lc8bcZ8JJnufstwM/rXHPDy5vd2N6dWytI9wmJznB/GljY8+n1rwxviz41bGfCS8f9O1xSf8LX8aY/5FJP8AwGuKl0JmyrQR79DyQeDitCHjlSA2Pzr52T4u+NkGF8Ip/wCAtxUv/C5PG+Mf8IfF/wCAtx/jUrDzJlViz6HKk5HGT6ioDAhBVlDKe1eA/wDC5vHH/QnxH/t1uP8AGk/4XL44z/yJ8X/gLcf41SoTJ9pE91ntliTiMhCe3OKoT22+N9i9OeteMH4x+OCDnwhF/wCAtxx+tVz8WvG3zY8JoN3X/RbirVGQe1R606nn5T/hUFy5YAtkFRjcDgkfhXkTfE3xiTn/AIRMf+A1xUbfEjxic/8AFK9f+nWeq9ky/bRPYIYEAIhAAA3Fs4/OpILgttUmNA3RWGC1eOf8LJ8Y5B/4RXkf9Os9PPxN8Zc/8UmMnubWeq9nITqxPagFT7wQZ9OtRyuFVmYY7Yrxc/Evxkf+ZV/8lZ6jf4jeMX4PhY49Pss+KXs5C9rE9YnuAWJJOOgBpsTEFTk7gcCvJD4/8XHH/FLNn/r1noXx/wCLl/5lY/8AgLPT9mxutE9gc7kbOM9gO1U3uMAg9jxXlJ8e+Ls8eGHH/brPUTeNvFhbd/wjD5/69ZqpQF7WJ6m8jP0/PikmkCJ94hiOfX6CvLl8ceLlII8Mvn/r1mpknjTxbIxZvDMmT3+yzcVXKL2sT0CVhnO45NcB8QPFn2SN9N02T/SGGJpFP3B/dHv/ACqnd+J/Fk8EkaaBPCzDAkS0lJX3GRXGSaJrTuWfSdTLE5JNrJyfyqo6ESqK2hmE5NJWl/YOsf8AQI1L/wABZP8ACj+wdY/6BGpf+Asn+FMxM2vXvg7/AMi1d/8AX43/AKLjrzP+wdY/6BGpf+Asn+Fes/CPStRg8O3SzadexsbtiA1u4ONie1AH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the distal esophagus showing an infiltrating and ulcerated circumferential lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41118=[""].join("\n");
var outline_f40_9_41118=null;
var title_f40_9_41119="Apoptotic programs";
var content_f40_9_41119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Caspase activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 416px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_9_41119=[""].join("\n");
var outline_f40_9_41119=null;
